Human monoclonal antibodies that widely target coronavirus

By developing monoclonal antibodies and antigen binding fragments that specifically bind coronavirus spike proteins, the existing technology has solved the problem of high resistance to Omicron variants and coping with multiple coronavirus variants, and achieved the goal of multiple coronaviruses. Effective neutralization and inhibition.

CN118984836APending Publication Date: 2024-11-19THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
View PDF 57 Cites 0 Cited by

Patent Information

Application Number
CN202380033468.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-10
Filing Date
2023-02-09
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing coronavirus vaccines and antibody therapies are highly resistant to concerning variants such as Omicron variants, and the possibility of coronavirus spillover from animal hosts exists, and a wider range of antibodies are needed to deal with multiple coronavirus variants. .

Method used

A set of monoclonal antibodies and antigen-binding fragments that specifically bind coronavirus spike proteins, including heavy chain variable regions and light chain variable regions, are developed to neutralize SARS-CoV-2 and other beta-coronavirus or alpha-coronaviruses Viruses, used to inhibit or detect coronavirus infection and provide nucleic acid molecules, vectors and pharmaceutical compositions encoding these antibodies and antigen binding fragments.

Benefits of technology

These monoclonal antibodies and antigen-binding fragments are able to effectively neutralize a variety of coronaviruses, including SARS-CoV-2 and its variants, provide a broader precaution, enhance the ability to inhibit coronavirus infection, and can be used for diagnosis and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005078060910000051
    Figure BDA0005078060910000051
  • Figure BDA0005078060910000053
    Figure BDA0005078060910000053
  • Figure BDA0005078060910000061
    Figure BDA0005078060910000061
Patent Text Reader

Abstract

Monoclonal antibodies and antigen binding fragments that specifically bind to coronavirus spike proteins, such as SARS-CoV-2, are disclosed. Also disclosed is the use of these antibodies in inhibiting coronavirus infection. In addition, methods of detecting coronavirus in a biological sample using the disclosed antibodies are disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 308,898, filed February 10, 2022, the entire contents of which are incorporated herein by reference.

[0003] Field of the Disclosure

[0004] The present disclosure relates to monoclonal antibodies and antigen-binding fragments that specifically bind to coronavirus spike proteins and their use in inhibiting or detecting coronavirus infection in a subject.

[0005] Citation of electronic sequence listing

[0006] The entire contents of the electronic Sequence Listing (4239-107907-02ST26 SL.xml; size: 432,282 bytes; creation date: February 4, 2023) are incorporated herein by reference.

[0007] background

[0008] The novel coronavirus SARS-CoV-2, which emerged in 2019, has infected 400 million people worldwide and caused over 5 million deaths. While effective vaccines and antibody therapies have been developed, their effectiveness remains threatened by the emergence of variants of concern, including the Omicron variant, which is more resistant to many of these tools than previous variants. Furthermore, the potential for further spillover of coronaviruses from animal reservoirs remains, necessitating preparation. Antibodies that bind to multiple coronaviruses remain in demand.

[0009] Overview of the Disclosure

[0010] A panel of human monoclonal antibodies (mAbs) targeting multiple coronaviruses has been isolated. These mAbs could be used to inhibit coronavirus infection, serve as prophylactics against coronavirus infection, and be a tool for developing next-generation vaccines that provide broader protection against coronaviruses.

[0011] Disclosed are isolated monoclonal antibodies or antigen-binding fragments that specifically bind to the coronavirus spike protein and neutralize SARS-CoV-2 and at least one additional betacoronavirus or alphacoronavirus.

[0012] Disclosed are isolated monoclonal antibodies or antigen-binding fragments thereof that specifically bind to the coronavirus spike protein. These monoclonal antibodies or antigen-binding fragments can neutralize at least one coronavirus.

[0013] In some embodiments, the antigen or antigen-binding fragment comprises a heavy chain variable region (V H ) and light chain variable region (V L ), which includes V as shown in any of the following H and V L Heavy chain complementarity determining regions (HCDR) 1, HCDR2 and HCDR3 and light chain complementarity determining regions (LCDR) 1, LCDR2 and LCDR3:

[0014] (a) SEQ ID NOs: 17 and 21 (COV44-79), respectively;

[0015] (b) SEQ ID NOs: 9 and 13 (COV44-62), respectively;

[0016] (c) SEQ ID NOs: 1 and 5 (COV89-22), respectively;

[0017] (d) SEQ ID NOs: 25 and 29 (COV30-14), respectively;

[0018] (e) SEQ ID NOs: 33 and 37 (COV72-37), respectively;

[0019] (f) SEQ ID NOs: 49 and 53 (COV91-27), respectively;

[0020] (g) SEQ ID NOs: 41 and 45 (COV93-03), respectively;

[0021] (h) SEQ ID NOs: 57 and 61 (COV49-51), respectively;

[0022] (i) SEQ ID NOs: 65 and 69 (COV44-74), respectively;

[0023] (j) SEQ ID NOs: 73 and 77 (COV44-56), respectively;

[0024] (k) SEQ ID NOs: 81 and 85 (COV44-26), respectively;

[0025] (l) SEQ ID NOs: 89 and 93 (COV44-54), respectively;

[0026] (m) SEQ ID NO: 97 and 101 (COV23-01), respectively;

[0027] (n) SEQ ID NOs: 105 and 109 (COV49-03), respectively;

[0028] (o) SEQ ID NOs: 113 and 117 (COV49-04), respectively;

[0029] (p) SEQ ID NOs: 121 and 125 (COV49-05), respectively;

[0030] (q) SEQ ID NOs: 129 and 133 (COV49-06), respectively;

[0031] (r) SEQ ID NOs: 137 and 141 (COV49-07), respectively;

[0032] (s) SEQ ID NO: 145 and 149 (COV49-18), respectively;

[0033] (t) SEQ ID NOs: 153 and 157 (COV49-23), respectively;

[0034] (u) SEQ ID NOs: 161 and 165 (COV49-28), respectively;

[0035] (v) SEQ ID NOs: 169 and 173 (COV49-30), respectively;

[0036] (w) SEQ ID NOs: 177 and 181 (COV49-33), respectively;

[0037] (x) SEQ ID NOs: 185 and 189 (COV49-42), respectively;

[0038] (y) SEQ ID NO: 193 and 197 (COV49-47), respectively;

[0039] (z) SEQ ID NOs: 201 and 205 (COV49-54), respectively;

[0040] (aa) SEQ ID NO: 209 and 213 (COV57-01), respectively;

[0041] (bb) SEQ ID NOs: 217 and 221 (COV57-03), respectively;

[0042] (cc) SEQ ID NOs: 225 and 229 (COV57-04), respectively;

[0043] (dd) SEQ ID NOs: 233 and 237 (COV57-05), respectively;

[0044] (ee) SEQ ID NO: 241 and 245 (COV57-13), respectively;

[0045] (ff) SEQ ID NOs: 249 and 253 (COV57-19), respectively;

[0046] (gg) SEQ ID NOs: 257 and 261 (COV57-34), respectively;

[0047] (hh) SEQ ID NOs: 265 and 269 (COV57-38), respectively;

[0048] (ii) SEQ ID NOs: 273 and 277 (COV57-45), respectively;

[0049] (jj) SEQ ID NOs: 281 and 285 (COV77-02), respectively;

[0050] (kk) SEQ ID NOs: 289 and 293 (COV77-04), respectively;

[0051] (ll) SEQ ID NO: 297 and 301 (COV77-05), respectively;

[0052] (mm) SEQ ID NO: 305 and 309 (COV77-09), respectively;

[0053] (nn) SEQ ID NOs: 313 and 317 (COV77-14), respectively;

[0054] (oo) SEQ ID NO: 321 and 325 (COV77-35), respectively;

[0055] (pp) SEQ ID NOs: 329 and 333 (COV77-39), respectively;

[0056] (qq) SEQ ID NO: 337 and 341 (COV77-42), respectively;

[0057] (rr) SEQ ID NOs: 345 and 349 (COV77-43), respectively;

[0058] (ss) SEQ ID NOs: 353 and 357 (COV77-46), respectively;

[0059] (tt) SEQ ID NO: 361 and 365 (COV77-76), respectively;

[0060] (uu) SEQ ID NO: 369 and 373 (COV93-04), respectively;

[0061] (vv) SEQ ID NOs: 377 and 381 (COV93-08), respectively;

[0062] (ww) SEQ ID NOs: 385 and 389 (COV93-17), respectively;

[0063] (xx) SEQ ID NO: 393 and 397 (COV93-18), respectively;

[0064] (yy) SEQ ID NO: 401 and 405 (COV93-23), respectively;

[0065] (zz) SEQ ID NO: 409 and 413 (COV78-36), respectively;

[0066] (aaa) SEQ ID NO: 417 and 421 (COV93-38), respectively;

[0067] (bbb) SEQ ID NOs: 425 and 429 (COV93-60), respectively;

[0068] (ccc) SEQ ID NOs: 433 and 437 (COV93-61), respectively;

[0069] (ddd) SEQ ID NO: 441 and 445 (COV89-03), respectively;

[0070] (eee) SEQ ID NOs: 449 and 453 (COV89-28), respectively;

[0071] (fff) SEQ ID NOs: 457 and 461 (COV30-35), respectively;

[0072] (ggg) SEQ ID NOs: 465 and 469 (COV30-80), respectively;

[0073] (hhh) SEQ ID NO: 473 and 477 (COV44-25), respectively; or

[0074] (iii) SEQ ID NO: 481 and 485 (COV44-37), respectively.

[0075] In some embodiments, nucleic acid molecules encoding these antibodies and antigen-binding fragments, vectors comprising these nucleic acid molecules, and host cells comprising these vectors are disclosed.

[0076] Also disclosed are pharmaceutical compositions comprising the antibodies, antigen-binding fragments, nucleic acid molecules, and carriers. In further embodiments, the use of these pharmaceutical compositions in inhibiting coronavirus infection in a subject is disclosed.

[0077] In other embodiments, use of the disclosed antibodies and antigen-binding fragments in detecting coronaviruses in biological samples is disclosed.

[0078] The above and other features and advantages of the present invention will become more apparent from the following detailed description of several embodiments with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0080] Figure 1 : Broadly reactive antibodies target multiple human coronaviruses. Heatmap depicts the binding of broadly reactive mAbs to different coronavirus spike proteins. Binding is shown for SARS-CoV-2 Wuhan Hu-1, SARS-CoV-1, MERS-CoV, HCoV-HKU1, HCoV-OC43 (betacoronavirus), HCoV-NL63, HCoV-229E (alphacoronavirus), and H1 hemagglutinin (control). Malaria mAb L9 was included as a negative control for mAb binding experiments (Wang, LT, et al. 2020). Area under the curve (AUC) values ​​for each antigen are shown after subtracting the value for the negative control antigen CD4.

[0081] Figure 2 The SARS-CoV-2 spike protein S2 subunit is a common target for broadly reactive antibodies. The heat map shows binding values ​​for selected domains within the SARS-CoV-2 spike protein: receptor binding domain (RBD), N-terminal domain (NTD), and S2 subunit (representative of n=1 experiment). Area under the curve (AUC) values ​​are shown after subtracting the value for the negative control antigen CD4.

[0082] Figure 3 : Broadly reactive mAbs target different epitopes within the SARS-CoV-2 S2 subunit. Surface plasmon resonance (SPR)-based binding analysis of the recombinant SARS-CoV-2 S2 subunit identified three different epitope bins (numbered in the inset) for broadly reactive mAbs. Dark grey boxes represent competing antibody pairs, light grey boxes represent non-competing antibody pairs, and hashed fillings represent self-competition.

[0083] Figures 4A-4B :Antibody fusion peptide with S2, stem-helix region and K814 +Site binding. SPR-based peptide scanning analysis identified the S2 fusion peptide (FP), stem helix (SH), and the N-terminal site (K814+) against the S2' cleavage site and fusion peptide region as three different epitopes targeted by broadly reactive mAbs. The heat map depicts the binding of (A) fusion peptide mAb and (B) stem helix mAb to an array of 15-mer peptides (which have a 12 amino acid overlap) covering the entire S2 subunit. Each column in the heat map represents a single peptide. White triangles represent the S1 / S2 cleavage site, and black triangles represent the S2' cleavage site. FP: fusion peptide; HR1: heptad repeat region 1; C helix: central helix; CD: connecting domain; SH: stem helix; HR2: heptad repeat region 2. In Figure 4A In, SEQ ID NO:491 is the amino acid sequence of peptide 42; SEQ ID NO:492 is the amino acid sequence of peptide 43; and SEQ ID NO:493 is the amino acid sequence of peptide 44. Figure 4B SEQ ID NO: 494 is the amino acid sequence of peptide 153; SEQ ID NO: 495 is the amino acid sequence of peptide 154; and SEQ ID NO: 496 is the amino acid sequence of peptide 155.

[0084] Figures 5A-5F Broadly reactive antibodies target highly conserved regions in coronavirus spike proteins. (A) Sequence conservation of the fusion peptide determined by alignment of spike protein sequences from 34 viral isolates representing a diverse panel of coronaviruses from four genera. (B) Sequence conservation of the stem-helix region determined by alignment of spike protein sequences from 28 viral isolates representing each of five betacoronavirus subgenera. Coloring in the heatmap indicates the percentage of amino acid residue identity. (CF) Figure 5A and Figure 5B The peptide sequences used in are provided as SEQ ID NOs: 499-562, see also Figures 5C to 5F .

[0085] Figures 6A-6B Broadly reactive antibodies neutralize multiple human coronaviruses and SARS-CoV-2 variants of concern. Neutralization of SARS-CoV-2 wild-type (WT) and variants of concern (pseudovirus) by (A) fusion peptide mAbs COV44-62 and COV44-79 and (B) stem-helix mAbs COV30-14, COV72-37, and COV89-22. Dashed lines indicate 50% neutralization. Error bars show mean ± standard deviation (SD).

[0086] Figures 7A-7BBroadly reactive antibodies inhibit SARS-CoV-2 spike-mediated target cell fusion. In vitro fusion inhibition was assessed in a quantitative assay using (A) fusion peptide mAbs (COV44-62, COV44-79, COV91-27, COV77-04, COV77-39, and COV78-36) and (B) stem-helix-specific mAbs (COV30-14, COV72-37, and COV89-22) and K814+-specific mAbs (COV77-43 and COV93-18). Malaria mAb L9 and CoV-2 RBD-specific mAb CV503 were used as negative controls.

[0087] Figures 8A-8B : Broadly reactive antibodies limit SARS-CoV-2-mediated pathology in hamsters. Body weight changes in Syrian hamsters exposed to SARS-CoV-2 after prophylaxis with individual (A) fusion peptide and (B) stem-helix mAbs. Statistical analysis was performed using a mixed-effects repeated measures model with Dunnett's post hoc multiple comparisons (n ​​= 12 animals for days 0 to 3 and n = 6 animals for days 4 to 7), and error bars represent mean ± SD. Bars show median ± interquartile range. *P < 0.05, **P < 0.01, ***P < 0.001, ***P < 0.0001, and ns, not significant.

[0088] Figure 9 A combination of fusion peptide and stem-helix antibodies limits SARS-CoV-2-mediated pathology in hamsters. Weight changes in Syrian hamsters exposed to SARS-CoV-2 (BA.2) after prophylaxis with a cocktail of fusion peptide and stem-helix mAbs. Bars show median ± interquartile range.

[0089] Figure 10 Table 1. Cross-reactive antibodies neutralize multiple human coronaviruses. Neutralization curves of cross-reactive antibodies against SARS-CoV-2 Wuhan-Hu-1, SARS-CoV-2 omicron variant, SARS-CoV-1, MERS-CoV, and NL63 envelope pseudotyped viruses. Curves are from representative cross-reactive antibodies. Error bars represent mean and SEM, and dashed lines indicate 50% neutralization.

[0090] sequence

[0091] As defined in 37 CFR 1.822, in the nucleic acid and amino acid sequences shown, nucleotide bases are represented by standard letter abbreviations, and amino acids are represented by three-letter codes. Only one strand of each nucleic acid sequence is shown, but the complementary strand should be understood to be included by any reference to the shown strand. In each heavy chain variable domain (VH ) and light chain variable domain (VL), the complementarity determining regions (CDRs) are shown in bold.

[0092] (a) SEQ ID NO: 1 is COV89-22 V H SEQ ID NOs: 2, 3 and 4 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0093]

[0094] SEQ ID NO: 5 is COV89-22V L SEQ ID NOs: 6, 7 and 8 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0095]

[0096] (b) SEQ ID NO: 9 is COV44-62 V H SEQ ID NOs: 10, 11 and 12 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0097]

[0098] SEQ ID NO: 13 is COV44-62 V L SEQ ID NOs: 14, 15 and 16 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0099]

[0100] (c) SEQ ID NO: 17 is COV44-79 V H SEQ ID NOs: 18, 19 and 20 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0101]

[0102] SEQ ID NO: 21 is COV44-79 V L SEQ ID NOs: 22, 23 and 24 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0103]

[0104] (d) SEQ ID NO: 25 is COV30-14 V H SEQ ID NOs: 26, 27 and 28 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0105]

[0106] SEQ ID NO: 29 is COV30-14 V L SEQ ID NOs: 30, 31 and 32 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0107]

[0108] (e) SEQ ID NO: 33 is COV72-37 V H SEQ ID NOs: 34, 35 and 36 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0109]

[0110] SEQ ID NO: 37 is COV72-37 V L SEQ ID NOs: 38, 39 and 40 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0111]

[0112] (f) SEQ ID NO: 41 is COV93-03 V H SEQ ID NOs: 42, 43 and 44 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0113]

[0114] SEQ ID NO: 45 is COV93-03 V L SEQ ID NOs: 46, 47 and 48 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0115]

[0116] (g) SEQ ID NO: 49 is COV91-27 V HSEQ ID NOs: 50, 51 and 52 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0117]

[0118] SEQ ID NO: 53 is COV91-27 V L SEQ ID NOs: 54, 55 and 56 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0119]

[0120] (h) SEQ ID NO: 57 is COV49-51 V H SEQ ID NOs: 58, 59 and 60 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0121]

[0122] SEQ ID NO:61 is COV49-51 V L SEQ ID NOs: 62, 63 and 64 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0123]

[0124] (i) SEQ ID NO: 65 is COV44-74 V H SEQ ID NOs: 66, 67 and 68 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0125]

[0126] SEQ ID NO: 69 is COV44-74 V L SEQ ID NOs: 70, 71 and 72 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0127]

[0128] (j) SEQ ID NO: 73 is COV44-56 V H SEQ ID NOs: 74, 75 and 76 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0129]

[0130] SEQ ID NO: 77 is COV44-56 V L SEQ ID NOs: 78, 79 and 80 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0131]

[0132] (k) SEQ ID NO: 81 is COV44-26 V H SEQ ID NOs: 82, 83 and 84 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0133]

[0134] SEQ ID NO:85 is COV44-26 V L SEQ ID NOs: 86, 87 and 88 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0135]

[0136] (1) SEQ ID NO: 89 is COV44-54 V H SEQ ID NOs: 90, 91 and 92 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0137]

[0138] SEQ ID NO:93 is COV44-54 V L SEQ ID NOs: 94, 95 and 96 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0139]

[0140] (m) SEQ ID NO: 97 is COV23-01 V H SEQ ID NOs: 98, 99 and 100 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0141]

[0142] SEQ ID NO: 101 is COV23-01 V L SEQ ID NOs: 102, 103 and 104 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0143]

[0144] (n) SEQ ID NO: 105 is COV49-03 V H SEQ ID NOs: 106, 107 and 108 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0145]

[0146] SEQ ID NO: 109 is COV49-03 V L SEQ ID NOs: 110, 111 and 112 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0147]

[0148] (o) SEQ ID NO: 113 is COV49-04 V H SEQ ID NOs: 114, 115 and 116 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0149]

[0150] SEQ ID NO: 117 is COV49-04 V L SEQ ID NOs: 118, 119 and 120 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0151]

[0152] (p) SEQ ID NO: 121 is COV49-05 V H SEQ ID NOs: 122, 123 and 124 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0153]

[0154] SEQ ID NO: 125 is COV49-05 V LSEQ ID NOs: 126, 127 and 128 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0155]

[0156] (q) SEQ ID NO: 129 is COV49-06 V H SEQ ID NOs: 130, 131 and 132 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0157]

[0158] SEQ ID NO: 133 is COV49-06 V L SEQ ID NOs: 134, 135 and 136 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0159]

[0160] (r) SEQ ID NO: 137 is COV49-07 V H SEQ ID NOs: 138, 139 and 140 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0161]

[0162] SEQ ID NO: 141 is COV49-07 V L SEQ ID NOs: 142, 143 and 144 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0163]

[0164] (s) SEQ ID NO: 145 is COV49-18 V H SEQ ID NOs: 146, 147 and 148 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0165]

[0166] SEQ ID NO: 149 is COV49-18 V LSEQ ID NOs: 150, 151 and 152 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0167]

[0168] (t) SEQ ID NO: 153 is COV49-23 V H SEQ ID NOs: 154, 155 and 156 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0169]

[0170] SEQ ID NO: 157 is COV49-23 V L SEQ ID NOs: 158, 159 and 160 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0171]

[0172] (u) SEQ ID NO: 161 is COV49-28 V H SEQ ID NOs: 162, 163 and 164 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0173]

[0174] SEQ ID NO: 165 is COV49-28 V L SEQ ID NOs: 166, 167 and 168 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0175]

[0176] (v) SEQ ID NO: 169 is COV49-30 V H SEQ ID NOs: 170, 171 and 172 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0177]

[0178] SEQ ID NO: 173 is COV49-30 V LSEQ ID NOs: 174, 175 and 176 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0179]

[0180] (w) SEQ ID NO: 177 is COV49-33 V H SEQ ID NOs: 178, 179 and 180 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0181]

[0182] SEQ ID NO: 181 is COV49-33 V L SEQ ID NOs: 182, 183 and 184 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0183]

[0184] (x) SEQ ID NO: 185 is COV49-42 V H SEQ ID NOs: 186, 187 and 188 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0185]

[0186] SEQ ID NO: 189 is COV49-42 V L SEQ ID NOs: 190, 191 and 192 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0187]

[0188] (y) SEQ ID NO: 193 is COV49-47 V H SEQ ID NOs: 194, 195 and 196 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0189]

[0190] SEQ ID NO: 197 is COV49-47 V LSEQ ID NOs: 198, 199 and 200 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0191]

[0192] (z) SEQ ID NO: 201 is COV49-54 V H SEQ ID NOs: 202, 203 and 204 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0193]

[0194] SEQ ID NO: 205 is COV49-54 V L SEQ ID NOs: 206, 207 and 208 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0195]

[0196] (aa) SEQ ID NO: 209 is COV57-01 V H SEQ ID NOs: 210, 211 and 212 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0197]

[0198] SEQ ID NO: 213 is COV57-01 V L SEQ ID NOs: 214, 215 and 216 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0199]

[0200] (bb) SEQ ID NO: 217 is COV57-03 V H SEQ ID NOs: 218, 219 and 220 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0201]

[0202] SEQ ID NO: 221 is COV57-03 V LSEQ ID NOs: 222, 223 and 224 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0203]

[0204] (cc) SEQ ID NO: 225 is COV57-04 V H SEQ ID NOs: 226, 227 and 228 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0205]

[0206] SEQ ID NO: 229 is COV57-04 V L SEQ ID NOs: 230, 231 and 232 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0207]

[0208] (dd) SEQ ID NO: 233 is COV57-05 V H SEQ ID NOs: 234, 235 and 236 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0209]

[0210] SEQ ID NO: 237 is COV57-05 V L SEQ ID NOs: 238, 239 and 240 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0211]

[0212] (ee) SEQ ID NO: 241 is COV57-13 V H SEQ ID NOs: 242, 243 and 244 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0213]

[0214] SEQ ID NO: 245 is COV57-13 V LSEQ ID NOs: 246, 247 and 248 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0215]

[0216] (ff) SEQ ID NO: 249 is COV57-19 V H SEQ ID NOs: 250, 251 and 252 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0217]

[0218] SEQ ID NO: 253 is COV57-19 V L SEQ ID NOs: 254, 255 and 256 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0219]

[0220] (gg) SEQ ID NO: 257 is COV57-34 V H SEQ ID NOs: 258, 259 and 260 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0221]

[0222] SEQ ID NO: 261 is COV57-34 V L SEQ ID NOs: 262, 263 and 264 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0223]

[0224] (hh) SEQ ID NO: 265 is COV57-38 V H SEQ ID NOs: 266, 267 and 268 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0225]

[0226] SEQ ID NO: 269 is COV57-38 V LSEQ ID NOs: 270, 271 and 272 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0227]

[0228] (ii) SEQ ID NO: 273 is COV57-45 V H SEQ ID NOs: 274, 275 and 276 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0229]

[0230] SEQ ID NO: 277 is COV57-45 V L SEQ ID NOs: 278, 279 and 280 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0231]

[0232] (jj) SEQ ID NO: 281 is COV77-02 V H SEQ ID NOs: 282, 283 and 284 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0233]

[0234] SEQ ID NO: 285 is COV77-02 V L SEQ ID NOs: 286, 287 and 288 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0235]

[0236] (kk) SEQ ID NO: 289 is COV77-04 V H SEQ ID NOs: 290, 291 and 292 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0237]

[0238] SEQ ID NO: 293 is COV77-04 V LSEQ ID NOs: 294, 295 and 296 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0239]

[0240] (11) SEQ ID NO: 297 is COV77-05 V H SEQ ID NOs: 298, 299 and 300 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0241]

[0242] SEQ ID NO: 301 is COV77-05 V L SEQ ID NOs: 302, 303 and 304 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0243]

[0244] (mm) SEQ ID NO: 305 is COV77-09 V H SEQ ID NOs: 306, 307 and 308 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0245]

[0246] SEQ ID NO: 309 is COV77-09 V L SEQ ID NOs: 310, 311 and 312 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0247]

[0248] (nn) SEQ ID NO: 313 is COV77-14 V H SEQ ID NOs: 314, 315 and 316 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0249]

[0250] SEQ ID NO: 317 is COV77-14 V LSEQ ID NOs: 318, 319 and 320 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0251]

[0252] (oo) SEQ ID NO: 321 is COV77-35 V H SEQ ID NOs: 322, 323 and 324 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0253]

[0254] SEQ ID NO: 325 is COV77-35 V L SEQ ID NOs: 326, 327 and 328 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0255]

[0256] (pp) SEQ ID NO: 329 is COV77-39 V H SEQ ID NOs: 330, 331 and 332 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0257]

[0258] SEQ ID NO: 333 is COV77-39 V L SEQ ID NOs: 334, 335 and 336 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0259]

[0260] (qq) SEQ ID NO: 337 is COV77-42 V H SEQ ID NOs: 338, 339 and 340 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0261]

[0262] SEQ ID NO: 341 is COV77-42 V LSEQ ID NOs: 342, 343 and 344 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0263]

[0264] (rr) SEQ ID NO: 345 is COV77-43 V H SEQ ID NOs: 346, 347 and 348 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0265]

[0266] SEQ ID NO: 349 is COV77-43 V L SEQ ID NOs: 350, 351 and 352 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0267]

[0268] (ss) SEQ ID NO: 353 is COV77-46 V H SEQ ID NOs: 354, 355 and 356 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0269]

[0270] SEQ ID NO: 357 is COV77-46 V L SEQ ID NOs: 358, 359 and 360 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0271]

[0272] (tt) SEQ ID NO: 361 is COV77-76 V H SEQ ID NOs: 362, 363 and 364 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0273]

[0274] SEQ ID NO: 365 is COV77-76 V LSEQ ID NOs: 366, 367 and 368 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0275]

[0276] (uu) SEQ ID NO: 369 is COV93-04 V H SEQ ID NOs: 370, 371 and 372 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0277]

[0278] SEQ ID NO: 373 is COV93-04 V L SEQ ID NOs: 374, 375 and 376 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0279]

[0280] (vv) SEQ ID NO: 377 is COV93-08 V H SEQ ID NOs: 378, 379 and 380 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0281]

[0282] SEQ ID NO: 381 is COV93-08 V L SEQ ID NOs: 382, ​​383 and 384 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0283]

[0284] (ww) SEQ ID NO: 385 is COV93-17 V H SEQ ID NOs: 386, 387 and 388 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0285]

[0286] SEQ ID NO: 389 is COV93-17 V LSEQ ID NOs: 390, 391 and 392 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0287]

[0288] (xx) SEQ ID NO: 393 is COV93-18 V H SEQ ID NOs: 394, 395 and 396 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0289]

[0290] SEQ ID NO: 397 is COV93-18 V L SEQ ID NOs: 398, 399 and 400 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0291]

[0292] (yy) SEQ ID NO: 401 is COV93-23 V H SEQ ID NOs: 402, 403 and 404 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0293]

[0294] SEQ ID NO: 405 is COV93-23 V L SEQ ID NOs: 406, 407 and 408 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0295]

[0296] (zz) SEQ ID NO: 409 is COV78-36 V H SEQ ID NOs: 410, 411 and 412 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0297]

[0298] SEQ ID NO: 413 is COV78-36 V LSEQ ID NOs: 414, 415 and 416 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0299]

[0300] (aaa) SEQ ID NO: 417 is COV93-38 V H SEQ ID NOs: 418, 419 and 420 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0301]

[0302] SEQ ID NO: 421 is COV93-38 V L SEQ ID NOs: 422, 423 and 424 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0303]

[0304] (bbb) SEQ ID NO: 425 is COV93-60 V H SEQ ID NOs: 426, 427 and 428 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0305]

[0306] SEQ ID NO: 429 is COV93-60 V L SEQ ID NOs: 430, 431 and 432 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0307]

[0308] (ccc) SEQ ID NO: 433 is COV93-61 V H SEQ ID NOs: 434, 435 and 436 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0309]

[0310] SEQ ID NO: 437 is COV93-61 V LSEQ ID NOs: 438, 439 and 440 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0311]

[0312] (ddd) SEQ ID NO: 441 is COV89-03 V H SEQ ID NOs: 442, 443 and 444 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0313]

[0314] SEQ ID NO: 445 is COV89-03 V L SEQ ID NOs: 446, 447 and 448 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0315]

[0316] (eee) SEQ ID NO: 449 is COV89-28 V H SEQ ID NOs: 450, 451 and 452 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0317]

[0318] SEQ ID NO: 453 is COV89-28 V L SEQ ID NOs: 454, 455 and 456 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0319]

[0320] (fff) SEQ ID NO: 457 is COV30-35 V H SEQ ID NOs: 458, 459 and 460 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0321]

[0322] SEQ ID NO: 461 is COV30-35 V LSEQ ID NOs: 462, 463 and 464 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0323]

[0324] (ggg) SEQ ID NO: 465 is COV30-80 V H SEQ ID NOs: 466, 467 and 468 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0325]

[0326] SEQ ID NO: 469 is COV30-80 V L SEQ ID NOs: 470, 471 and 472 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0327]

[0328] (hhh) SEQ ID NO: 473 is COV44-25 V H SEQ ID NOs: 474, 475 and 476 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0329]

[0330] SEQ ID NO: 477 is COV44-25 V L SEQ ID NOs: 478, 479 and 480 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0331]

[0332] (iii) SEQ ID NO: 481 is COV44-37 V H SEQ ID NOs: 482, 483 and 484 are the amino acid sequences of HCDR1, HCDR2 and HCDR3, respectively.

[0333]

[0334] SEQ ID NO: 485 is COV44-37 V LSEQ ID NOs: 486, 487 and 488 are the amino acid sequences of LCDR1, LCDR2 and LCDR3, respectively.

[0335]

[0336] SEQ ID NOs: 489 and 490 are the amino acid sequences of the stem helix in the S2 domain of the spike protein of the coronavirus.

[0337] LQPELDSFKEELDKYFKNHTS

[0338] LDSFKEELDKYF

[0339] SEQ ID NO: 491 is the amino acid sequence of peptide 42.

[0340] PSKPSKRSFIEDLLF

[0341] SEQ ID NO:492 is the amino acid sequence of peptide 43.

[0342] PSKRSFIEDLLFNKV

[0343] SEQ ID NO:493 is the amino acid sequence of peptide 44.

[0344] RSFIEDLLFNKVTLA

[0345] SEQ ID NO:494 is the amino acid sequence of peptide 153.

[0346] QPELDSFKEELDKYF

[0347] SEQ ID NO:495 is the amino acid sequence of peptide 154.

[0348] LDSFKEELDKYFKNH

[0349] SEQ ID NO:496 is the amino acid sequence of peptide 155.

[0350] FKEELDKYFKNHTSP

[0351] SEQ ID NO: 497 is the amino acid sequence (partial) of the fusion peptide site.

[0352] SFIEDLLFNKVTLA

[0353] SEQ ID NO: 498 is the amino acid sequence of the S2 peptide.

[0354] RSFIEDLLF

[0355] SEQ ID NO: 499-532 are peptide sequences from coronavirus spike protein and are Figures 5C-5F Shown in.

[0356] Detailed description of several implementation schemes

[0357] Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and to the spike protein of at least one other coronavirus (such as an alpha coronavirus or a beta coronavirus). In some embodiments, the monoclonal antibodies bind to the S2 domain of the spike protein. Also disclosed are bispecific antibodies. These monoclonal antibodies and bispecific antibodies can be used to inhibit coronavirus infection (such as, but not limited to, SARS-CoV-2 infection). Monoclonal antibodies and bispecific antibodies can also be used to detect coronavirus infection.

[0358] I. Overview of Terminology

[0359] Unless otherwise indicated, technical terms are used according to conventional usage. Definitions of many common terms in molecular biology can be found in Krebs et al. (eds.), Lewin's genes XII, published by Jones & Bartlett Learning, 2017. As used herein, the singular forms "a", "an" and "the" refer to both the singular and the plural, unless the context clearly indicates otherwise. For example, the term "an antigen" includes one or more antigens and can be considered equivalent to the phrase "at least one antigen". As used herein, the term "comprising" means "including". It should also be understood that, unless otherwise indicated, any and all base sizes or amino acid sizes and all molecular weight or molecular mass values ​​given for nucleic acids or polypeptides are approximate and are provided for descriptive purposes. Although many methods and materials similar or equivalent to the methods and materials described herein can be used, particularly suitable methods and materials are described herein. In the event of a conflict, this specification (including the explanation of the terms) shall prevail. In addition, materials, methods and examples are illustrative only and not restrictive. For ease of reference to various embodiments, the following term explanations are provided:

[0360] About: Unless the context indicates otherwise, "about" refers to ±5% of the reference value. For example, "about" 100 means 95 to 105.

[0361] Administration: Introducing an agent (e.g., a disclosed antibody) into a subject via a selected route. Administration can be local or systemic. For example, if the selected route is an intravascular route, the agent (e.g., antibody) is administered by introducing the composition into the subject's blood vessels. Exemplary routes of administration include, but are not limited to, oral, injection (e.g., subcutaneous, intramuscular, intradermal, intraperitoneal, and intravenous), sublingual, rectal, transdermal (e.g., topical), intranasal, vaginal, and inhalation routes.

[0362] Amino acid substitution: replacing an amino acid in a peptide with a different amino acid.

[0363] Antibodies and antigen-binding fragments: immunoglobulins, antigen-binding fragments, or derivatives thereof, that specifically bind to and recognize an analyte (antigen), such as a coronavirus spike protein (such as a spike protein from SARS-CoV-2). The term "antibody" is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antigen-binding fragments, as long as they exhibit the desired antigen-binding activity.

[0364] Non-limiting examples of antibodies include, for example, intact immunoglobulins and variants and fragments thereof that retain binding affinity for the antigen. Antigen binding fragments include V H and V L And specifically bind to the same family (cognate) antigen. Examples of antigen-binding fragments include, but are not limited to: Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed by antibody fragments. Antibody fragments include antigen-binding fragments produced by modifying whole antibodies or antigen-binding fragments synthesized de novo using recombinant DNA methods (e.g., see Kontermann and Dübel (Eds.), Antibody Engineering, Vols. 1-2, 2 nd ed., Springer-Verlag, 2010).

[0365] Antibodies also include genetically engineered forms, such as chimeric antibodies (eg, humanized murine antibodies) and heteroconjugate antibodies (eg, bispecific antibodies).

[0366] An antibody may have one or more binding sites. If there is more than one binding site, these binding sites may be identical or different. For example, naturally occurring immunoglobulins have two identical binding sites, single-chain antibodies or Fab fragments have one binding site, and bispecific or bifunctional antibodies have two different binding sites.

[0367] Typically, naturally occurring immunoglobulins have heavy (H) chains and light (L) chains interconnected by disulfide bonds. Immunoglobulin genes include genes for the κ (kappa), λ (lambda), α (alpha), γ (gamma), δ (delta), ε (epsilon), and μ (mu) constant regions, as well as numerous immunoglobulin variable domain genes. There are two types of light chains: lambda (λ) and kappa (κ). There are five major heavy chain types (or isotypes) that determine the functional activity of antibody molecules: IgM, IgD, IgG, IgA, and IgE.

[0368] Each heavy chain and light chain contains a constant region (or constant domain) and a variable region (or variable domain). The heavy chain variable region and the light chain variable region work together to specifically bind to the antigen.

[0369] Mention "V H " or "VH" refers to the variable region of an antibody heavy chain, including the variable region of an antigen-binding fragment (such as Fv, scFv, dsFv or Fab). L ” or “VL” refers to the variable region of an antibody light chain, including the variable region of an Fv, scFv, dsFv, or Fab.

[0370] V H and V L It contains a "framework" region, also called a "complementarity determining region" or "CDR" (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 5 th ed., NIH Publication No. 91-3242, Public Health Service, National Institutes of Health, US Department of Health and Human Services, 1991). The sequences of the framework regions of different light or heavy chains are relatively conserved across species. The framework region of an antibody (i.e., the combined framework regions of the light and heavy chains) serves to position and align the CDRs in three-dimensional space.

[0371] The CDRs are primarily responsible for binding to the epitope of the antigen. The amino acid sequence boundaries of a given CDR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (Sequences of Proteins of Immunological Interest, 5 thed., NIH Publication No. 91-3242, Public Health Service, National Institutes of Health, US Department of Health and Human Services, 1991; "Kabat" numbering scheme), Al-Lazikani et al. ("Standard conformations for the canonical structures of immunoglobulins," J. Mol. Bio., 273(4):927-948, 1997; "Chothia" numbering scheme), and Lefranc et al. ("IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," Dev. Comp. Immunol., 27(1):55-77, 2003; "IMGT" numbering scheme). The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3 (from N-terminus to C-terminus) and are also typically identified by the chain in which a particular CDR is located. Thus, V H CDR3 is derived from the V H CDR3, while V L CDR1 is derived from the V L Light chain CDRs are sometimes referred to as LCDR1, LCDR2, and LCDR3. Heavy chain CDRs are sometimes referred to as HCDR1, HCDR2, and HCDR3.

[0372] In some embodiments, the disclosed antibodies comprise a heterologous constant domain. For example, the antibody comprises a constant domain that is different from a native constant domain, such as a constant domain that comprises one or more modifications (such as an "LS" mutation) to increase half-life.

[0373] "Monoclonal antibody" is an antibody obtained from a substantially homogeneous antibody population, that is, the individual antibodies making up the population are identical and / or bind to the same epitope, except for example containing naturally occurring mutations or possible variant antibodies formed during the production of monoclonal antibody preparations, which are typically present in trace amounts. In contrast to polyclonal antibody preparations that typically contain different antibodies for different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed to a single determinant on the antigen. Therefore, the modifier "monoclonal" indicates that the characteristic of the antibody is obtained from a substantially homogeneous antibody population and should not be understood as requiring the production of antibodies by any specific method. For example, monoclonal antibodies can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin locus, which methods and other exemplary methods for preparing monoclonal antibodies are described herein. In some instances, monoclonal antibodies are isolated from a subject. Monoclonal antibodies can have conservative amino acid substitutions that have substantially no effect on antigen binding or other immunoglobulin functions. (See, for example, Greenfield (Ed.), Antibodies: A Laboratory Manual, 2 nd ed. New York: ColdSpring Harbor Laboratory Press, 2014.)

[0374] "Humanized" antibodies or antigen-binding fragments comprise a human framework region and one or more CDRs from a non-human (such as mouse, rat or synthetic) antibody or antigen-binding fragment. The non-human antibody or antigen-binding fragment providing the CDR is called a "donor," and the human antibody or antigen-binding fragment providing the framework is called an "acceptor." In one embodiment, in a humanized immunoglobulin, all CDRs are from a donor immunoglobulin. Constant regions do not need to be present, but if present, they can be substantially identical to human immunoglobulin constant regions, such as at least about 85% to 90% (such as about 95% or more) identical. Therefore, all parts of a humanized antibody or antigen-binding fragment (possibly with the exception of the CDRs) are substantially identical to corresponding parts of natural human antibody sequences.

[0375] A "chimeric antibody" is an antibody that comprises sequences derived from two different antibodies, which generally belong to different species. In some instances, a chimeric antibody comprises one or more CDRs and / or framework regions from one human antibody and CDRs and / or framework regions from another human antibody.

[0376] A "fully human antibody" or "human antibody" is an antibody that comprises sequences from (or derived from) the human genome and does not comprise sequences from another species. In some embodiments, a human antibody comprises CDRs, framework regions, and (if present) an Fc region from (or derived from) the human genome. Human antibodies can be identified and isolated using techniques for producing antibodies based on sequences derived from the human genome (e.g., by phage display or using transgenic animals) (see, e.g., Barbas et al. Phage display: A Laboratory Manuel. 1996). st Ed. New York: Cold Spring Harbor Laboratory Press, 2004. Print.; Lonberg, Nat. Biotech., 23: 1117-1125, 2005; Lonenberg, Curr. Opin. Immunol., 20: 450-459, 2008).

[0377] Neutralizing coronavirus antibodies or antigen-binding fragments: antibodies or antigen-binding fragments that specifically bind to coronavirus antigens (such as spike proteins) to inhibit biological functions associated with coronaviruses, thereby inhibiting infection. The antibody can neutralize the activity of one or more coronaviruses. For example, antibodies or antigen-binding fragments that neutralize coronaviruses (such as SARS-CoV-2) can interfere with the virus by directly binding to the virus and restricting its entry into cells. Alternatively, the antibody can interfere with one or more post-attachment interactions between the pathogen and the receptor, for example, by interfering with viral entry using the receptor. In some instances, antibodies specific for the coronavirus spike protein can neutralize the infectious titer of the coronavirus.

[0378] In some embodiments, the antibody or antigen-binding fragment that specifically binds to and neutralizes a coronavirus inhibits cell infection by, for example, at least 50%, compared to a control antibody or antigen-binding fragment.

[0379] "Broadly neutralizing antibodies" are antibodies that bind to and inhibit the function of a related antigen (e.g., an antigen that has at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the antigenic surface of the antigen). For antigens from pathogens (e.g., viruses), the antibody can bind to and inhibit the function of antigens from more than one class and / or subclass of the pathogen. For example, for a coronavirus, the antibody can bind to an antigen (e.g., the spike protein from the coronavirus) and inhibit the function of the antigen.

[0380] Biological sample: A sample obtained from a subject. Biological samples include all clinical samples that can be used to detect disease or infection in a subject, including but not limited to cells, tissues, body fluids (such as blood, blood derivatives and components (such as serum), and cerebrospinal fluid), and tissue removed by biopsy or surgery (e.g., tissue that is unfixed, frozen, or fixed in formalin or paraffin). In a specific example, a biological sample is obtained from a subject who has or is suspected of having a coronavirus infection (such as, but not limited to, SARS-CoV-2 infection).

[0381] Bispecific antibodies: recombinant molecules composed of two different antigen-binding domains, thereby binding to two different antigenic epitopes. Bispecific antibodies include molecules composed of two antigen-binding domains that are chemically linked or genetically linked. The antigen-binding domains can be connected using a linker. The antigen-binding domains can be monoclonal antibodies, antigen-binding fragments (e.g., Fab and scFv), or a combination thereof. Bispecific antibodies can contain one or more constant domains, but do not necessarily contain constant domains.

[0382] Conditions sufficient to form an immune complex: Conditions that allow an antibody or antigen-binding fragment to bind to its cognate epitope to a detectably greater extent than to substantially all other epitopes and / or to the substantial exclusion of binding to substantially all other epitopes. Conditions sufficient to form an immune complex depend on the mode of binding reaction and are generally those utilized in immunoassay protocols or those encountered in vivo. For a description of immunoassay formats and conditions, see Greenfield (Ed.), Antibodies: A Laboratory Manual, 2 nd Ed. New York: Cold Spring Harbor Laboratory Press, 2014. The conditions used in the methods are "physiological conditions," including reference to conditions typical of living mammals or mammalian cells (e.g., temperature, osmolarity, and pH). Although some organs are known to be subjected to extreme conditions, the intracellular environment in living organisms is typically around pH 7 (e.g., pH 6.0 to pH 8.0, more typically pH 6.5 to pH 7.5), contains water as the primary solvent, and exists at a temperature above 0°C and below 50°C. Osmolarity is within a range that supports cell survival and proliferation.

[0383] The formation of immune complexes can be detected by conventional methods (e.g., immunohistochemistry (IHC), immunoprecipitation (IP), flow cytometry, immunofluorescence microscopy, ELISA, immunoblotting (e.g., Western blot), magnetic resonance imaging (MRI), computed tomography (CT), radiography, and affinity chromatography).

[0384] Conjugate: A complex consisting of two molecules that are linked together (e.g., linked together by a covalent bond). In one embodiment, an antibody is linked to an effector molecule; for example, an antibody that specifically binds to one or more coronaviruses (such as SARS-CoV-2) is covalently linked to an effector molecule (such as a detectable label). The connection can be performed chemically or recombinantly. In one embodiment, the connection is a chemical connection, wherein the reaction between the antibody portion and the effector molecule produces a covalent bond formed between the two molecules, thereby forming one molecule. A peptide linker (a short peptide sequence) may optionally be included between the antibody and the effector molecule. Because conjugates can be prepared from two molecules with different functions (such as an antibody and an effector molecule), conjugates are sometimes also referred to as "chimeric molecules."

[0385] Conservative variants: "Conservative" amino acid substitutions are those that do not substantially affect or reduce protein function (such as the ability of the protein to interact with the target protein). For example, a coronavirus-specific antibody can contain up to 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10 conservative substitutions compared to a reference antibody sequence and retain specific binding activity and / or neutralizing activity against the spike protein. The term "conservative variation" also includes the replacement of an unsubstituted parent amino acid with a substituted amino acid.

[0386] Individual substitutions, deletions, or additions that change, add, or delete a single amino acid or a small number of amino acids (e.g., less than 5%, in some embodiments less than 1%) in a coding sequence are conservative variations when these changes result in the substitution of an amino acid with a chemically similar amino acid.

[0387] The following six groups are examples of amino acids that are considered conservative substitutions for each other:

[0388] (1) Alanine (A), serine (S) and threonine (T);

[0389] (2) aspartic acid (D) and glutamic acid (E);

[0390] (3) asparagine (N) and glutamine (Q);

[0391] (4) Arginine (R) and Lysine (K);

[0392] (5) isoleucine (I), leucine (L), methionine (M), and valine (V); and

[0393] (6) Phenylalanine (F), tyrosine (Y) and tryptophan (W).

[0394] Non-conservative substitutions are those that reduce the activity or function of the antibody (such as the ability to specifically bind to the coronavirus spike protein). For example, if an amino acid residue is essential for the function of the protein, even an otherwise conservative substitution may disrupt that activity. Therefore, conservative substitutions do not alter the essential function of the protein of interest.

[0395] Contact: Placed in direct physical association; includes both solid and liquid forms and can occur in vivo or in vitro. Contact includes contact between one molecule and another, such as contact between amino acids on the surface of one polypeptide (such as an antigen) and another polypeptide (such as an antibody). Contact can also include contacting a cell, for example, by placing an antibody in direct physical association with the cell.

[0396] Control: A reference standard. In some embodiments, the control is a negative control, such as a sample obtained from a healthy patient who has not been infected with the coronavirus. In other embodiments, the control is a positive control, such as a tissue sample obtained from a patient diagnosed with a coronavirus infection. In other embodiments, the control is a historical control or a standard reference value or range of values ​​(such as a previously tested control sample, such as a group of patients with a known prognosis or outcome, or a group of samples representing baseline or normal values).

[0397] The difference between the test sample and the control can be an increase or conversely a decrease. The difference can be a qualitative difference or a quantitative difference (e.g., a statistically significant difference). In some instances, the difference is an increase or decrease of at least about 5% relative to the control (e.g., at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 150%, at least about 200%, at least about 250%, at least about 300%, at least about 350%, at least about 400%, or at least about 500%).

[0398] Coronavirus: A family of positive-sense, single-stranded RNA viruses known to cause severe respiratory illness. Currently, viruses in the coronavirus family known to infect humans are from the alphacoronavirus and betacoronavirus genera. Additionally, it is believed that gammacoronavirus and deltacoronavirus may infect humans in the future.

[0399] Non-limiting examples of beta coronaviruses include SARS-CoV-2, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), human coronavirus HKU1 (HKU1-CoV), human coronavirus OC43 (OC43-CoV), mouse hepatitis virus (MHV-CoV), bat SARS-like coronavirus WIV1 (WIV1-CoV) and human coronavirus HKU9 (HKU9-CoV). Non-limiting examples of alpha coronaviruses include human coronavirus 229E (229E-CoV), human coronavirus NL63 (NL63-CoV), porcine epidemic diarrhea virus (PEDV) and transmissible gastroenteritis coronavirus (TGEV). A non-limiting example of delta coronavirus is porcine delta coronavirus (SDCV).

[0400] The viral genome is capped, polyadenylated, and covered by the nucleocapsid protein. The coronavirus particle includes a viral envelope containing a type I fusion glycoprotein called the spike (S) protein. Most coronaviruses share a common genomic organization with the replicase gene.

[0401] Degenerate variants: In the context of this disclosure, "degenerate variants" refers to polynucleotides encoding polypeptides (such as antibody heavy or light chains) that include sequences that are degenerate due to the genetic code. There are 20 naturally occurring amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences encoding peptides are encompassed, as long as the amino acid sequence of the peptide encoded by the nucleotide sequence remains unchanged.

[0402] Detectable marker: A detectable molecule (also called a label) that is coupled directly or indirectly to a second molecule (such as an antibody) to facilitate detection of the second molecule. For example, a detectable marker can be detected by ELISA, spectrophotometry, flow cytometry, microscopy, or diagnostic imaging techniques (such as CT scan, MRI, ultrasound, fiberoptic examination, and laparoscopy). Specific non-limiting examples of detectable markers include fluorophores, chemiluminescent agents, enzymatic linkages, radioisotopes, and heavy metals or compounds (e.g., superparamagnetic iron oxide nanocrystals for MRI detection). For example, in Green and Sambrook (Molecular Cloning: A Laboratory Manual, 4 thMethods of using detectable markers and guidelines for selecting detectable markers for various purposes are discussed in

[15] ,

[16] ,

[17] ,

[18] ,

[19] ,

[20] ,

[21] ,

[22] ,

[23] ,

[24] ,

[25] ,

[26] ,

[27] ,

[28] ,

[29] ,

[30] ,

[31] ,

[32] ,

[33] ,

[34] ,

[35] ,

[36] ,

[37] ,

[38] ,

[39] ,

[40] ,

[41] ,

[42] ,

[43] ,

[44] ,

[45] ,

[46] ,

[47] ,

[48] ,

[49] ,

[50] ,

[51] ,

[52] ,

[53] ,

[54] ,

[55] ,

[56] ,

[57] ,

[58] ,

[59] ,

[60] , [61

[0403] Detect: To confirm the existence, occurrence, or fact of something.

[0404] Effective Amount: An amount of a particular substance sufficient to achieve a desired effect in a subject to which it is administered. For example, this may be the amount necessary to inhibit a coronavirus infection (such as SARS-CoV-2) or to measurably alter the outward symptoms of such an infection.

[0405] In one example, the expected response is to inhibit, reduce or prevent SARS-CoV-2 infection. The method does not need to be effective when SARS-CoV-2 infection is completely eliminated, reduced or prevented. For example, compared to a suitable control, administration of an effective amount of an immunogen can induce an immune response that reduces SARS-CoV-2 infection (e.g., measured by the number or percentage of infected cells or subjects infected with SARS-CoV-2), for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or even at least 100% (eliminating or preventing detectable SARS-CoV-2 infection). Due to the use of the currently disclosed antibodies, other coronavirus infections can also be inhibited.

[0406] In some embodiments, administration of an effective amount of a disclosed antibody or antigen-binding fragment that binds to a coronavirus spike protein can reduce or inhibit infection (e.g., as measured by the number or percentage of infected cells, or subjects infected with a coronavirus, or an increase in the survival of infected subjects, or a reduction in symptoms associated with infection) by an amount desired, for example, at least 10%, at least 20%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or even at least 100% (elimination or prevention of detectable infection) compared to a suitable control.

[0407] The effective amount of an antibody or antigen-binding fragment (which specifically binds to the coronavirus spike protein) administered to a subject to inhibit infection will vary depending on many factors associated with the subject (e.g., the subject's overall health and / or weight). The effective amount can be determined by varying the dosage and measuring the resulting response (such as, for example, a reduction in pathogen titer). The effective amount can also be determined by various in vitro, in vivo, or in situ immunoassays.

[0408] The effective dose encompasses split doses, which contribute to obtaining an effective response in combination with previous or subsequent administration. For example, in a course of treatment that lasts for several days or weeks, the reagent of an effective dose can be administered in a single dose or multiple doses (e.g., every day). However, the effective dose can depend on the severity and type of the patient's condition being treated, and on the mode of administration. The unit dosage form of the reagent can be packaged in an amount or in multiples of an effective dose, for example, in a vial (e.g., with a pierceable cap) or a syringe with sterile ingredients.

[0409] Effector molecule: A molecule designed to have or produce a desired effect (e.g., a desired effect on a cell or detectable marker targeted by the effector molecule). Effector molecules can include, for example, polypeptides and small molecules. Some effector molecules can have or produce more than one desired effect.

[0410] Epitope: Antigenic determinant. These are specific chemical groups or peptide sequences on a molecule that are antigenic, making them eliciting a specific immune response; for example, an epitope is the region of an antigen to which B and / or T cells respond. Antibodies can bind to specific epitopes (such as those on the coronavirus spike protein).

[0411] Expression: The transcription or translation of a nucleic acid sequence. For example, when DNA encoding a nucleic acid sequence (such as a gene) is transcribed into RNA or RNA fragments (which in some instances are processed into mRNA), the encoding nucleic acid sequence can be expressed. When mRNA encoding a nucleic acid sequence (such as a gene) is translated into an amino acid sequence (such as a protein or protein fragment), the encoding nucleic acid sequence can also be expressed. In a specific example, a heterologous gene is expressed when it is transcribed into RNA. In another example, a heterologous gene is expressed when its RNA is translated into an amino acid sequence. Regulation of expression can include control of transcription, translation, RNA transport and processing, control of degradation of intermediate molecules (such as mRNA), or control through activation, inactivation, compartmentalization, or degradation of specific protein molecules after production.

[0412] Expression control sequence: a nucleic acid sequence that regulates the expression of its operably linked heterologous nucleic acid sequence. When expression control sequences control and regulate the transcription and (as the case may be) translation of a nucleic acid sequence, these expression control sequences are operably connected to the nucleic acid sequence. Therefore, an expression control sequence can include a suitable promoter, an enhancer, a transcription terminator, a start codon (ATG) before a protein-coding gene, a splicing signal for introns, a correct reading frame for the gene maintained for correct translation of mRNA, and a stop codon. The term "control sequence" is intended to include at least components whose presence can affect expression, and can also include other components whose presence is beneficial (e.g., a leader sequence and a fusion partner sequence). An expression control sequence can include a promoter.

[0413] Expression vector: A vector comprising a recombinant polynucleotide comprising expression control sequences operably linked to a nucleotide sequence to be expressed. An expression vector comprises sufficient cis-acting elements for expression; other elements for expression may be provided by the host cell or in an in vitro expression system. Non-limiting examples of expression vectors include cosmids, plasmids (e.g., naked plasmids or plasmids contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate a recombinant polynucleotide.

[0414] The polynucleotide can be inserted into an expression vector containing a promoter sequence that facilitates the host to efficiently transcribe the inserted genetic sequence. Expression vectors typically contain a replication origin, a promoter, and specific nucleic acid sequences that allow selection of the transformed cell phenotype.

[0415] Fc region: The constant region of an antibody, which does not include the first heavy chain constant domain. The Fc region generally refers to the last two heavy chain constant domains of IgA, IgD and IgG, and the last three heavy chain constant domains of IgE and IgM. The Fc region may also include part or all of the flexible hinge at the N-terminus of these domains. For IgA and IgM, the Fc region may or may not include a tailpiece and may be bound or not bound by the J chain. For IgG, the Fc region is generally understood to include the lower portion of the hinge between the immunoglobulin domains Cγ2, Cγ3, and optionally Cγ1 and Cγ2. Although the boundaries of the Fc region may vary, the human IgG heavy chain Fc region is generally defined as including residues after C226 or P230 to the carboxyl terminus of the Fc, where the numbering is based on the EU numbering. For IgA, the Fc region includes the lower portion of the hinge between the immunoglobulin domains Cα2, Cα3, and optionally Cα1 and Cα2.

[0416] Heterologous: Derived from a different genetic source. A nucleic acid molecule heterologous to a cell originates from a genetic source other than the cell in which the nucleic acid molecule is expressed. In a specific, non-limiting example, a heterologous nucleic acid molecule encoding a protein (such as an scFv) is expressed in a cell (such as a mammalian cell). Methods for introducing heterologous nucleic acid molecules into cells or organisms are well known in the art, such as by nucleic acid transformation, including electroporation, lipofection, particle gun acceleration, and homologous recombination.

[0417] Host cell: A cell in which a vector can be propagated and its DNA expressed. This cell can be either prokaryotic or eukaryotic. The term also includes any progeny of the subject host cell. It should be understood that due to the possibility of mutations arising during replication, all progeny may differ from the parent cell. However, when the term "host cell" is used, such progeny are also included.

[0418] IgA: A polypeptide belonging to the class of antibodies that is primarily encoded by the recognized immunoglobulin alpha gene. In humans, this class, or isotype, includes IgA1 and IgA2. IgA antibodies can exist as monomers, polymers that are primarily dimers (called pIgA), and secretory IgA. The invariant chain of wild-type IgA contains an 18-amino acid extension at its C-terminus, called the tail piece (tp). Multimeric IgA is secreted by plasma cells and has a 15-kDa peptide called the J chain that connects the two monomers of IgA via a conserved cysteine ​​residue in the tail piece.

[0419] IgG: A polypeptide belonging to the antibody class or isotype substantially encoded by the recognized immunoglobulin gamma genes. In humans, the classes include IgG1, IgG2, IgG3, and IgG4.

[0420] Immune complex: The binding of an antibody or antigen-binding fragment (such as scFv) to a soluble antigen forms an immune complex. The formation of immune complexes can be detected by conventional methods (e.g., immunohistochemistry, immunoprecipitation, flow cytometry, immunofluorescence microscopy, ELISA, immunoblotting (e.g., Western blot), magnetic resonance imaging, CT scanning, radiography, and affinity chromatography).

[0421] Inhibit or treat disease: For example, inhibiting the full development of a disease or condition in a subject at risk of developing the disease (such as a coronavirus infection). "Treatment" refers to a therapeutic intervention that improves the signs or symptoms of a disease or pathological condition after it has begun to develop. With respect to a disease or pathological condition, the term "improvement" refers to any observable beneficial effect of treatment. Inhibiting a disease can include preventing or reducing the risk of a disease (such as preventing or reducing the risk of a viral infection). This beneficial effect can be demonstrated, for example, by a delayed onset of clinical symptoms of the disease in a susceptible subject, a reduction in the severity of some or all of the clinical symptoms of the disease, a slowing of disease progression, a reduction in viral load, an improvement in the overall health or well-being of the subject, or other parameters for a specific disease. "Preventive" treatment is a treatment administered to a subject who does not show signs of the disease or only shows early signs in order to reduce the risk of developing a condition.

[0422] The term "reduce" is a relative term, so an agent can reduce a disease or condition if the disease or condition is quantitatively reduced after administration (compared to a reference agent) or the disease or condition is attenuated after administration. Similarly, the term "prevent" does not necessarily mean that the agent completely eliminates the disease or condition, as long as at least one characteristic of the disease or condition is eliminated. Thus, a composition that reduces or prevents an infection can, but does not necessarily, completely eliminate the infection, as long as the infection is measurably reduced, for example, by at least about 50% (such as at least about 70%, about 80%, or even about 90%) of the infection in the absence of the agent or by at least about 50% (such as at least about 70%, about 80%, or even about 90%) compared to a reference agent.

[0423] Isolated: A biological component that has been substantially separated, produced or purified from other biological components (i.e., other chromosomal and extrachromosomal DNA and RNA, and proteins) in the cells of an organism in which the biological component (such as a nucleic acid, peptide, protein, or protein complex, e.g., an antibody) naturally occurs. Thus, isolated nucleic acids, peptides, and proteins include nucleic acids and proteins purified by standard purification methods. The term also includes nucleic acids, peptides, and proteins prepared by recombinant expression in a host cell, as well as chemically synthesized nucleic acids. An isolated nucleic acid, peptide, or protein (e.g., an antibody) can be at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% pure.

[0424] Kabat position: The position of the residue in the amino acid sequence, following the numbering convention described by Kabat et al. (Sequences of Proteins of Immunological Interest, 5 th Edition, Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, NIH Publication No. 91-3242, 1991).

[0425] Linker: A bifunctional molecule that can be used to join two molecules into one continuous molecule (e.g., linking a detectable marker to an antibody). Non-limiting examples of peptide linkers include glycine-serine linkers.

[0426] The terms "couple," "bind," "bond," or "link" may refer to the formation of two molecules into a single continuous molecule; for example, linking two polypeptides into a single continuous polypeptide, or covalently attaching an effector molecule, a detectable marker, a radionuclide, or other molecule to a polypeptide, such as an scFv. Linking can be accomplished chemically or recombinantly. "Chemical" refers to the reaction between the antibody portion and the effector molecule, resulting in the formation of a covalent bond between the two molecules to form a single molecule.

[0427] Nucleic acid (molecule or sequence): a deoxyribonucleotide or ribonucleotide polymer or a combination thereof, including but not limited to cDNA, mRNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA or RNA. Nucleic acids can be double-stranded (ds) or single-stranded (ss). In the case of a single strand, the nucleic acid can be a sense strand or an antisense strand. Nucleic acids can include natural nucleotides (e.g., A, T / U, C, and G) and can include analogs of natural nucleotides (e.g., labeled nucleotides).

[0428] "cDNA" refers to a single- or double-stranded form of DNA that is complementary or identical to mRNA.

[0429] "Coding" refers to the inherent properties of a specific nucleotide sequence in a polynucleotide (such as a gene, cDNA or mRNA) as a template for synthesizing other polymers and macromolecules in a biological process, and these polymers and macromolecules have a definite nucleotide (i.e., rRNA, tRNA and mRNA) sequence or a definite amino acid sequence and the resulting biological properties. Therefore, if the transcription and translation of the mRNA produced by a gene produce a protein in a cell or other biological system, the gene encodes a protein. The coding strand (its nucleotide sequence is identical to the mRNA sequence, and is generally provided in a sequence table) and the non-coding strand (used as a transcription template) of a gene or cDNA can be referred to as a protein or other product encoding the gene or cDNA. Unless otherwise indicated, "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate forms and encode the same amino acid sequence. The nucleotide sequence of coded proteins and RNA can include introns.

[0430] Operably linked: A first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first and second nucleic acid sequences are in a functional relationship. For example, a promoter (such as the CMV promoter) is operably linked to a coding sequence if it affects the transcription or expression of the coding sequence. Typically, operably linked DNA sequences are contiguous and in the same reading frame when it is desired to combine two protein coding regions.

[0431] Pharmaceutically acceptable carriers: Useful pharmaceutically acceptable carriers are conventional. In Remington: The Science and Practice of Pharmacy, 22 nd Compositions and formulations suitable for drug delivery of the disclosed agents are described in Pharmaceutical Press, ed., London, UK: Pharmaceutical Press, 2013.

[0432] In general, the character of the carrier will depend on the specific mode of administration adopted. For example, parenteral preparations generally include injectable fluids, and injectable liquids include pharmaceutically and physiologically acceptable fluids (such as water, physiological saline, balanced salt solution, dextrose (dextrose) aqueous solution or glycerol etc. as solvents). For solid compositions (for example, powder, pill, tablet or capsule form), conventional non-toxic solid carriers can include for example pharmaceutical grade mannitol, lactose, starch or magnesium stearate. In addition to biological neutral carriers, pharmaceutical compositions to be administered can contain a small amount of non-toxic adjuvants (such as wetting agents or emulsifiers, preservatives (such as non-natural preservatives) and pH buffers etc., such as sodium acetate or sorbitol monolaurate). In specific examples, pharmaceutically acceptable carriers are sterile and are suitable for parenteral administration (such as by injection) to experimenters. In some embodiments, activating agent and pharmaceutically acceptable carrier are provided in unit dosage form (such as pill) or in the selected amount in a bottle. A unit dosage form may comprise one or more doses (eg, packaged in a vial from which a metered dose of an agent can be selectively dispensed).

[0433] Polypeptide: A polymer in which the monomers are amino acid residues, which are bound together by amide bonds. When the amino acid is an α-amino acid, either the L-optical isomer or the D-optical isomer can be used, with the L-isomer being preferred. As used herein, the terms "polypeptide" or "protein" are intended to encompass any amino acid sequence, and include modified sequences (such as glycoproteins). Polypeptides include both naturally occurring proteins and proteins produced recombinantly or synthetically. Polypeptides have an amino terminal (N-terminal) end and a carboxyl terminal end. In some embodiments, the polypeptide is a disclosed antibody or a fragment thereof.

[0434] Purified: The term "purified" does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified peptide preparation is one in which the peptide or protein (such as an antibody) is more enriched than the peptide or protein in its natural environment within a cell. In one embodiment, the preparation is purified such that the protein or peptide constitutes at least 50% of the total peptide or protein content of the preparation.

[0435] Recombination: recombinant nucleic acid is a nucleic acid with a sequence that is not naturally occurring or with a sequence that is artificially combined by two otherwise separated sequence fragments. This artificial combination can be achieved by chemical synthesis or more commonly by artificially operating separated nucleic acid fragments (for example, by genetic engineering technology). Recombinant protein is a protein with a sequence that is not naturally occurring or with a sequence that is artificially combined by two otherwise separated sequence fragments. In a number of embodiments, recombinant protein is encoded by a heterologous (for example, recombinant) nucleic acid that has been introduced into a host cell (such as a bacterial cell or a eukaryotic cell). The nucleic acid can be introduced into an expression vector, for example, with a signal that can express a protein encoded by the introduced nucleic acid, or the nucleic acid can be integrated into the host cell chromosome.

[0436] SARS-CoV-2: Also known as the Wuhan coronavirus or the 2019 novel coronavirus, SARS-CoV-2 is a positive-sense, single-stranded RNA virus of the genus Betacoronavirus that has become a highly lethal cause of severe acute respiratory infections. The viral genome is capped, polyadenylated, and covered by the nucleocapsid protein. The SARS-CoV-2 virion consists of a viral envelope with a large spike glycoprotein. Like most coronaviruses, the SARS-CoV-2 genome has a common genomic organization, with the replicase genes contained within the 5'-terminal two-thirds of the genome and the structural genes within the 3'-terminal third of the genome. The SARS-CoV-2 genome encodes a standard set of structural protein genes in the order 5'-spike (S)-envelope (E)-membrane (M), and nucleocapsid (N)-3'. Symptoms of SARS-CoV-2 infection include fever and respiratory illness (such as a dry cough and shortness of breath). Severe cases can progress to severe pneumonia, multi-organ failure, and death. The time from exposure to symptom onset is approximately 2 to 14 days.

[0437] Standard methods for detecting viral infections can be used to detect SARS-CoV-2 infection, including but not limited to assessment of the patient's symptoms and background and genetic testing (such as reverse transcription-polymerase chain reaction (rRT-PCR)). The test can be performed on patient samples (such as respiratory or blood samples).

[0438] Spike (S) protein (coronavirus): A class I fusion glycoprotein initially synthesized as a precursor protein of approximately 1256 amino acids for SARS-CoV and 1273 amino acids for SARS-CoV-2. The individual precursor S polypeptides form homotrimers and undergo glycosylation and processing in the Golgi apparatus to remove the signal peptide. They are cleaved by cellular proteases between approximately positions 679 / 680 (SARS-CoV) and 685 / 686 (SARS-CoV-2) to produce separate S1 and S2 polypeptide chains, which remain associated as S1 / S2 protomers within the homotrimer, resulting in a trimer composed of heterodimers. The S1 subunit is located distal to the viral membrane and contains the receptor-binding domain (RBD), which is thought to mediate viral attachment to its host receptor. The S2 subunit contains the fusion protein machinery, such as a fusion peptide, two heptad repeats (HR1 and HR2), a central helix characteristic of fusion glycoproteins, a transmembrane domain, and a cytoplasmic tail.

[0439] exist An exemplary sequence of the SARS-CoV S protein is provided in GI:30795145 (available on February 1, 2022). An exemplary sequence of the HKU1-CoV S protein is provided in GI:123867264 (available on February 1, 2022). An exemplary sequence of the OC43-CoV S protein is provided in GI:744516696 (available on February 1, 2022). An exemplary sequence of the NL63-CoV S protein is provided in GI:71153773 (available on February 1, 2022). An exemplary sequence of the 229E-CoV S protein is provided in GI: 1060650120 (available on February 1, 2022). The S protein comprises an S1 domain and an S2 domain.

[0440] The numbering used in the disclosed SARS-CoV-2 S protein and fragments thereof corresponds to the S protein of SARS-CoV-2, the sequence of which is deposited as NCBI Ref. No. YP_009724390.1 (available on February 1, 2022), the entire contents of which are incorporated herein by reference.

[0441] Sequence identity: The identity between two or more nucleic acid sequences or two or more amino acid sequences is expressed as a percentage of identity between the sequences. Sequence identity can be measured as a percentage of identity; the higher the percentage, the more identical the sequences are. Lor V H Homologs and variants of the present invention are typically characterized by having at least about 75% sequence identity (e.g., having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity calculated over the entire length of the amino acid sequence of interest).

[0442] Any suitable method can be used to align sequences for comparison. Non-limiting examples of programs and alignment algorithms are described in the following: Smith and Waterman, Adv. Appl. Math. 2(4): 482-489, 1981; Needleman and Wunsch, J. Mol. Biol. 48(3): 443-453, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85(8): 2444-2448, 1988; Higgins and Sharp, Gene, 73(1): 237-244, 1988; Higgins and Sharp, Bioinformatics, 5(2): 151-3, 1989; Corpet, Nucleic Acids Res. 16(22): 10881-10890, 1988; Huang et al. al. Bioinformatics, 8(2):155-165, 1992; and Pearson, Methods Mol. Biol. 24:307-331, 1994., Altschul et al., J. Mol. Biol. 215(3):403-410, 1990, provide detailed considerations of sequence alignment methods and homology calculations. The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol. 215(3):403-410, 1990) is available from a variety of sources, including the National Center for Biological Information and the Internet, for use in conjunction with the sequence analysis programs blastp, blastn, blastx, tblastn, and tblastx. Blastn is used to compare nucleic acid sequences, while blastp is used to compare amino acid sequences. More information can be found on the NCBI website.

[0443] Typically, once two sequences are aligned, the number of matches is determined by counting the number of positions where the same nucleotide or amino acid residue is present in the two sequences. The percent sequence identity between the two sequences is determined by dividing the number of matches by the length of the sequence in the identified sequence or by the articulated length (e.g., 100 consecutive nucleotides or amino acid residues of the sequence in the identified sequence) and multiplying the resulting value by 100.

[0444] Specific binding: When referring to an antibody or antigen-binding fragment, refers to a binding reaction that determines the presence of a target protein in the presence of a heterogeneous population of proteins and other biologics. Thus, under specified conditions, the antibody preferentially binds to a specific target protein, peptide, or polysaccharide, such as an antigen present on the surface of a pathogen (e.g., the coronavirus spike protein), and does not bind in significant amounts to other proteins present in the sample or subject. With respect to spike proteins, epitopes can be present on the spike proteins of more than one coronavirus, such that the antibody can bind to spike proteins of more than one virus, but will not bind to other proteins, such as proteins from other viruses or other proteins (non-spike proteins) of the coronavirus. Specific binding can be determined by standard methods. See "Harlow & Lane, Antibodies, A Laboratory Manual, 2 nd ed., Cold Spring Harbor Publications, New York (2013)", describes immunoassay formats and conditions that can be used to determine specific immunoreactivity.

[0445] With respect to antibody-antigen complexes, the specific binding of antigen and antibody has a specific binding affinity of less than about 10 -7 molar (e.g. less than about 10 -8 Moore, 10 -9 molar or even less than about 10 -10 molar) K D .K D Refers to the dissociation constant for a given interaction (e.g., a polypeptide-ligand interaction or an antibody-antigen interaction). For example, for a bimolecular interaction between an antibody or antigen-binding fragment and an antigen, it is equal to the concentration of the individual components of the bimolecular interaction divided by the concentration of the complex.

[0446] Antibodies that specifically bind to epitopes on the coronavirus spike protein (such as the S domain, RBD domain, or NTD domain) can bind to molecules / reagents containing this domain (including viruses, substrates to which the spike protein is attached, or proteins in biological specimens). Of course, it is well known that a certain degree of non-specific interaction may occur between antibodies and non-targets. Generally, specific binding makes the association between the antibody and the spike protein much stronger than the association between the antibody and other different coronavirus proteins (such as E, M, or N proteins) or non-coronavirus proteins. Specific binding will typically increase the amount of antibody bound to proteins containing the epitope or cells or tissues expressing the target epitope (per unit time) by more than 2 times (for example, more than 5 times, more than 10 times, or more than 100 times) compared to proteins or cells or tissues lacking the epitope. Specific binding to proteins under these conditions requires antibodies selected for their specificity for a particular protein. Various immunoassay formats are suitable for selecting antibodies or other ligands that specifically immunoreact with specific proteins. For example, solid-phase ELISA immunoassays are commonly used to select monoclonal antibodies that specifically immunoreact with proteins.

[0447] Subject: A living multicellular vertebrate organism, which is a class including humans and non-human mammals (e.g., non-human primates, pigs, camels, bats, sheep, cattle, dogs, cats, rodents, etc.). In one example, the subject is a human. In a specific example, the subject is a human. In another example, a subject is selected in whom SARS-CoV-2 infection is to be inhibited. For example, the subject is either uninfected but at risk of infection with SARS-CoV-2, or is already infected and in need of treatment.

[0448] Transformation: A transformed cell is a cell into which a nucleic acid molecule has been introduced by molecular biology techniques. As used herein, the term "transformation" and the like (e.g., conversion, transfection, transduction, etc.) encompass all techniques by which a nucleic acid molecule can be introduced into such a cell, including transduction with viral vectors, transformation with plasmid vectors, and DNA introduction by electroporation, lipofection, and particle gun acceleration.

[0449] Vector: An entity containing a nucleic acid molecule (such as a DNA or RNA molecule) with one or more promoters that is operably linked to the coding sequence of the protein of interest and capable of expressing the coding sequence. Non-limiting examples include naked DNA or packaged (lipid and / or protein) DNA, naked RNA or packaged RNA, a subcomponent of a virus, bacteria or other microorganism that may not have the ability to replicate, or a virus, bacteria or other microorganism that may have the ability to replicate. A vector is sometimes referred to as a construct. A recombinant DNA vector is a vector with recombinant DNA. The vector may contain a nucleic acid sequence (such as a replication origin) that allows it to replicate in a host cell. The vector may also contain one or more selective marker genes and other genetic elements. A viral vector is a recombinant nucleic acid vector having at least some nucleic acid sequences derived from one or more viruses. In some embodiments, the viral vector includes a nucleic acid molecule encoding a disclosed antibody or antigen-binding fragment that specifically binds to a coronavirus spike protein and neutralizes a coronavirus. In some embodiments, the viral vector may be an adeno-associated virus (AAV) vector.

[0450] Under conditions sufficient to: A phrase used to describe any circumstances that permit the intended activity.

[0451] II. Description of Several Implementation Options

[0452] Provided are isolated monoclonal antibodies and antigen-binding fragments that specifically bind to the coronavirus spike protein. These monoclonal antibodies and antigen-binding fragments specifically bind to the coronavirus spike protein and neutralize SARS-CoV-2 and at least one other betacoronavirus or alphacoronavirus. These antibodies and antigen-binding fragments can be completely human antibodies and antigen-binding fragments. These antibodies and antigen-binding fragments can neutralize coronaviruses (such as, but not limited to, SARS-CoV-2). In some embodiments, the disclosed antibodies can inhibit coronavirus infection in vivo and can be administered before or after infection with a coronavirus (such as, but not limited to, SARS-CoV-2). Also provided are bispecific antibodies comprising the variable domains of these antibodies. In addition, compositions are disclosed herein, comprising antibodies and antigen-binding fragments and pharmaceutically acceptable carriers. Also provided are nucleic acids encoding these antibodies, antigen-binding fragments, and variable domains, as well as expression vectors comprising these nucleic acids (such as adeno-associated virus (AAV) viral vectors). These antibodies, antigen-binding fragments, nucleic acid molecules, host cells, and compositions can be used for research, diagnosis, treatment, and prevention purposes. For example, the disclosed antibodies and antigen-binding fragments can be used to diagnose a subject having a coronavirus infection, or can be administered to inhibit a coronavirus infection in a subject.

[0453] A. Monoclonal antibodies and antigen-binding fragments thereof that specifically bind to coronavirus spike protein

[0454] The following discussion of monoclonal antibodies relates to isolated monoclonal antibodies comprising heavy and / or light chain variable domains (or antigen-binding fragments thereof) including CDR1, CDR2, and / or CDR3 according to the IMGT numbering scheme (unless the context indicates otherwise). Various CDR numbering schemes (such as Kabat, Chothia, or IMGT numbering schemes) can be used to determine CDR positions. The amino acid sequences and CDRs of the heavy and light chains of the disclosed monoclonal antibodies according to the IMGT numbering scheme are provided in the sequence listing, but these are exemplary only.

[0455] In some embodiments, monoclonal antibodies are provided that include the heavy chain CDRs and light chain CDRs of any of the antibodies described herein. In some embodiments, monoclonal antibodies are provided that include the heavy chain and light chain variable regions of any of the antibodies described herein.

[0456] In some embodiments, the antibody binds to the N-terminal domain of the coronavirus spike protein. In other embodiments, the antibody binds to the S domain of the coronavirus spike protein. In further embodiments, the antibody binds to the stem helix in the S2 domain of the spike protein, such as LQPELDSFKEELDKYFKNHTS (SEQ ID NO: 489), such as LDSFKEELDKYF (SEQ ID NO: 490).

[0457] In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1, and OC43. In other embodiments, the antibody or antigen-binding fragment can neutralize betacoronaviruses and alphacoronaviruses. In further embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1, OC43, NL63, and 229E.

[0458] Binding data for the antibodies described below are shown in the accompanying figures.

[0459] a. Monoclonal antibody COV44-79

[0460] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV44-79 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0461] In some examples, the antibody or antigen-binding fragment comprises V H and V L (including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV44-79 antibodies, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize a coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment can neutralize betacoronavirus and alphacoronavirus. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1, OC43, NL63 and 229E.

[0462] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 17), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 21), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 17 and 21), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0463] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 18, 19 and 20, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 22, 23, and 24, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0464] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 18, 19 and 20, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 22, 23 and 24, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 17 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 17), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 21 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 21), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0465] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 17), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 21), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 17 and 21, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0466] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0467] b. Monoclonal antibody COV44-62

[0468] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV44-62 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some examples, the antibody or antigen-binding fragment includes V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV44-62 antibodies, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize a coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment can neutralize betacoronavirus and alphacoronavirus. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1, OC43, NL63 and 229E.

[0469] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 9), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 13), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 9 and 13), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0470] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 10, 11 and 12, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 14, 15, and 16, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0471] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 10, 11 and 12, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 14, 15 and 16, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 9 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 9), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 13 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 13), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0472] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 9), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 13), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 9 and 13, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0473] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0474] c. Monoclonal antibody COV89-22

[0475] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV89-22 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0476] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV89-22 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43. In some embodiments, the antibody or antigen-binding fragment can neutralize beta coronaviruses and alpha coronaviruses. In some embodiments, the antibody or antigen-binding fragment specifically binds to the stem-helix in the S2 domain of the spike protein.

[0477] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 1), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 5), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 1 and 5), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0478] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 2, 3 and 4, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 6, 7 and 8, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0479] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 2, 3 and 4, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 6, 7 and 8, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 1 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 1), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 5 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0480] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 1), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 5), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 1 and 5, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0481] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0482] d. Monoclonal antibody COV30-14

[0483] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV30-14 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0484] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV30-14 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43. In some embodiments, the antibody or antigen-binding fragment can neutralize beta coronaviruses and alpha coronaviruses. In some embodiments, the antibody or antigen-binding fragment specifically binds to the stem-helix in the S2 domain of the spike protein.

[0485] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 25), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 29), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences having at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identity to the amino acid sequences set forth in SEQ ID NOs: 25 and 29), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0486] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 26, 27 and 28, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 30, 31 and 32, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0487] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 26, 27 and 28, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 30, 31 and 32, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 25 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 25), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 29 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 29), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0488] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 25), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 29), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 25 and 29, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0489] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0490] e. Monoclonal antibody COV72-37

[0491] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV72-37 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0492] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV72-37 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43. In some embodiments, the antibody or antigen-binding fragment can neutralize beta coronaviruses and alpha coronaviruses. In some embodiments, the antibody or antigen-binding fragment specifically binds to the stem-helix in the S2 domain of the spike protein.

[0493] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 33), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 37), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences having at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identity to the amino acid sequences set forth in SEQ ID NOs: 33 and 37), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0494] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 34, 35 and 36, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 38, 39 and 40, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0495] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 34, 35 and 36, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 38, 39 and 40, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 33 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 33), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 37 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 37), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0496] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 33), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 37), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 33 and 37, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0497] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0498] f. Monoclonal antibody COV91-27

[0499] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV91-27 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0500] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV91-27 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1, OC43, NL63 and 229E. In some embodiments, the antibody or antigen-binding fragment can neutralize betacoronavirus and alphacoronavirus.

[0501] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 49), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 53), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences having at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identity to the amino acid sequences set forth in SEQ ID NOs: 49 and 53), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0502] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 50, 51 and 52, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 54, 55 and 56, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0503] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 50, 51 and 52, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 54, 55 and 56, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 49 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 49), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 53 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 53), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0504] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 49), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 53), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 49 and 53, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0505] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0506] g. Monoclonal antibody COV93-03

[0507] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV93-03 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0508] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV93-03 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43. In some embodiments, the antibody or antigen-binding fragment can neutralize beta coronaviruses and alpha coronaviruses. In some embodiments, the antibody or antigen-binding fragment specifically binds to the stem-helix in the S2 domain of the spike protein.

[0509] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 41), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 45), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences having at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identity to the amino acid sequences set forth in SEQ ID NOs: 41 and 45), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0510] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 42, 43 and 44, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 46, 47 and 48, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0511] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 42, 43 and 44, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 46, 47 and 48, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 41 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 41), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 45 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 45), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0512] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 41), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 45), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 41 and 45, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0513] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0514] h. Monoclonal antibody COV49-51

[0515] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-51 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0516] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV49-51 antibodies, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43. In some embodiments, the antibody or antigen-binding fragment can neutralize beta coronaviruses and alpha coronaviruses. In some embodiments, the antibody or antigen-binding fragment specifically binds to the stem-helix in the S2 domain of the spike protein.

[0517] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 57), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 61), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 57 and 61), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0518] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 58, 59 and 60, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 62, 63 and 64, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0519] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 58, 59 and 60, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 62, 63 and 64, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 57 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 57), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 61 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 61), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0520] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 57), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 61), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 57 and 61, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0521] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0522] i. Monoclonal antibody COV44-74

[0523] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV44-74 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0524] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV44-74 antibodies, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43. In some embodiments, the antibody or antigen-binding fragment can neutralize beta coronaviruses and alpha coronaviruses. In some embodiments, the antibody or antigen-binding fragment specifically binds to the stem-helix in the S2 domain of the spike protein.

[0525] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 65), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 69), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences having at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identity to the amino acid sequences set forth in SEQ ID NOs: 65 and 69), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0526] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 66, 67 and 68, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 70, 71 and 72, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0527] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 66, 67 and 68, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 70, 71 and 72, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 65 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 65), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 69 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 69), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0528] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 65), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 69), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 65 and 69, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0529] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0530] j. Monoclonal antibody COV44-56

[0531] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV44-56 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0532] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV44-56 antibodies, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43. In some embodiments, the antibody or antigen-binding fragment can neutralize beta coronaviruses and alpha coronaviruses. In some embodiments, the antibody or antigen-binding fragment specifically binds to the stem-helix in the S2 domain of the spike protein.

[0533] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 73), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 77), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences having at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identity to the amino acid sequences set forth in SEQ ID NOs: 73 and 77) and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0534] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 74, 75 and 76, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 78, 79 and 80, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0535] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 74, 75 and 76, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 78, 79 and 80, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 73 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 73), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 77 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 77), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0536] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 73), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 77), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 73 and 77, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0537] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0538] k. Monoclonal antibody COV44-26

[0539] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV44-26 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0540] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV44-26 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43. In some embodiments, the antibody or antigen-binding fragment can neutralize beta coronaviruses and alpha coronaviruses. In some embodiments, the antibody or antigen-binding fragment specifically binds to the stem-helix in the S2 domain of the spike protein.

[0541] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 81), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 85), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 81 and 85), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0542] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 82, 83 and 84, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 86, 87 and 88, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0543] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 82, 83 and 84, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 86, 87 and 88, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 81 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 81), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 85 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 85), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0544] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 81), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 85), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 81 and 85, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0545] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0546] 1. Monoclonal antibody COV44-54

[0547] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV44-54 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0548] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV44-54 antibodies, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43. In some embodiments, the antibody or antigen-binding fragment can neutralize beta coronaviruses and alpha coronaviruses. In some embodiments, the antibody or antigen-binding fragment specifically binds to the stem-helix in the S2 domain of the spike protein.

[0549] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 89), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 93), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 89 and 93), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0550] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 90, 91 and 92, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO:94, 95 and 96, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0551] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 90, 91 and 92, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 94, 95 and 96, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 89 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 89), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 93 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 93), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0552] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 89), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 93), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 89 and 93, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0553] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0554] m. Monoclonal antibody COV23-01

[0555] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV23-01 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0556] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV23-01 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0557] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 97), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 101), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 97 and 101), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0558] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 98, 99 and 100, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 102, 103, and 104, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0559] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 98, 99 and 100, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 102, 103 and 104, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 97 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 97), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 101 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 101), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0560] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 97), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 101), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 97 and 101, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0561] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0562] n. Monoclonal antibody COV49-03

[0563] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-03 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0564] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV49-03 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0565] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 105), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 109), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 105 and 109), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0566] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 106, 107 and 108, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 110, 111, and 112, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0567] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 106, 107 and 108, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 110, 111 and 112, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 105 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 109 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 109), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0568] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 105), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 109), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 105 and 109, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0569] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0570] o. Monoclonal antibody COV49-04

[0571] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-04 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0572] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV49-04 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0573] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 113), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 117), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 113 and 117), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0574] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 114, 115 and 116, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 118, 119, and 120, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0575] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 114, 115 and 116, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 118, 119 and 120, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 113 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 113), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 117 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 117), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0576] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 113), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 117), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 113 and 117, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0577] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0578] p. Monoclonal antibody COV49-05

[0579] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-05 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0580] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV49-05 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0581] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 121), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 125), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 121 and 125), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0582] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 122, 123 and 124, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 126, 127, and 128, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0583] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 122, 123 and 124, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 126, 127 and 128, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 121 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 121), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 125 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 125), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0584] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 121), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 125), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 121 and 125, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0585] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0586] q. Monoclonal antibody COV49-06

[0587] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-06 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0588] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV49-06 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0589] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 129), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 133), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 129 and 133), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0590] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 130, 131 and 132, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 134, 135 and 136, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0591] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 130, 131 and 132, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 134, 135 and 136, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 129 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 129), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 133 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 133), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0592] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 129), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 133), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 129 and 133, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0593] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0594] r. Monoclonal antibody COV49-07

[0595] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-07 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0596] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV49-07 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0597] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 137), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 141), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (respectively and independently comprising an amino acid sequence having at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identity to the amino acid sequence shown in SEQ ID NO: 137 and 141) and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0598] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 138, 139 and 140, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 142, 143 and 144, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0599] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 138, 139 and 140, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 142, 143 and 144, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 137 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 137), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 141 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 141), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0600] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 137), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 141), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 137 and 141, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0601] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0602] s. Monoclonal antibody COV49-18

[0603] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-18 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0604] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV49-18 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0605] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 145), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 149), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 145 and 149), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0606] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 146, 147 and 148, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 150, 151 and 152, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0607] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 146, 147 and 148, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 150, 151 and 152, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 145 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 145), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 149 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 149), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0608] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 145), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 149), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 145 and 149, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0609] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0610] t. Monoclonal antibody COV49-23

[0611] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-23 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0612] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV49-23 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0613] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 153), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 157), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 153 and 157), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0614] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 154, 155 and 156, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 158, 159 and 160, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0615] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 154, 155 and 156, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 158, 159 and 160, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 153 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 153), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 157 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 157), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0616] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 153), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 157), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 153 and 157, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0617] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0618] u. Monoclonal antibody COV49-28

[0619] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-28 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0620] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV49-28 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0621] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 161), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 165), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 161 and 165), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0622] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 162, 163 and 164, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 166, 167, and 168, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0623] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 162, 163 and 164, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 166, 167 and 168, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 161 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 161), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 165 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 165), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0624] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 161), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 165), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 161 and 165, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0625] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0626] v. Monoclonal antibody COV49-30

[0627] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-30 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0628] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV49-30 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0629] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 169), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 173), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 169 and 173), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0630] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 170, 171 and 172, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 174, 175 and 176, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0631] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 170, 171 and 172, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 174, 175 and 176, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 169 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 169), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 173 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 173), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0632] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 169), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 173), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 169 and 173, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0633] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0634] w. Monoclonal antibody COV49-33

[0635] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-33 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0636] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV49-33 antibodies, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0637] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 177), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 181), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 177 and 181), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0638] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 178, 179 and 180, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 182, 183 and 184, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0639] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 178, 179 and 180, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 182, 183 and 184, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 177 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 177), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 181 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 181), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0640] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 177), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 181), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 177 and 181, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0641] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0642] x. Monoclonal antibody COV49-42

[0643] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-42 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0644] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV49-42 antibodies, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0645] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 185), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 189), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 185 and 189), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0646] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 186, 187 and 188, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 190, 191 and 192, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0647] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 186, 187 and 188, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 190, 191 and 192, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 185 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 185), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 189 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 189), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0648] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 185), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 189), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 185 and 189, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0649] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0650] y. Monoclonal antibody COV49-47

[0651] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-47 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0652] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV49-47 antibodies, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0653] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 193), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 197), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 193 and 197), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0654] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 194, 195 and 196, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 198, 199 and 200, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0655] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 194, 195 and 196, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 198, 199 and 200, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 193 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 193), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 197 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 197), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0656] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 193), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 197), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 193 and 197, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0657] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0658] z. Monoclonal antibody COV49-54

[0659] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV49-54 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0660] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV49-54 antibodies, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0661] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 201), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 205), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 201 and 205), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0662] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 202, 203 and 204, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 206, 207, and 208, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0663] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 202, 203 and 204, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 206, 207 and 208, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 201 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 205 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 205), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0664] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 201), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 205), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 201 and 205, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0665] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0666] aa. Monoclonal antibody COV57-01

[0667] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV57-01 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0668] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV57-01 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0669] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 209), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 213), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 209 and 213), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0670] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 210, 211 and 212, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 214, 215, and 216, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0671] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 210, 211 and 212, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 214, 215 and 216, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 209 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 213 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 213), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0672] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 209), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 213), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 209 and 213, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0673] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0674] bb. Monoclonal antibody COV57-03

[0675] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV57-03 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0676] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV57-03 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0677] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 217), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 221), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 217 and 221), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0678] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 218, 219 and 220, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 222, 223, and 224, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0679] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 218, 219 and 220, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 222, 223 and 224, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 217 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 221 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 221), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0680] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 217), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 221), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 217 and 221, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0681] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0682] cc. Monoclonal antibody COV57-04

[0683] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV57-04 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0684] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV57-04 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0685] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 225), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 229), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 225 and 229), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0686] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 226, 227 and 228, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 230, 231, and 232, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0687] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 226, 227 and 228, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 230, 231 and 232, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 225 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 229 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 229), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0688] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 225), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 229), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 225 and 229, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0689] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0690] dd. Monoclonal antibody COV57-05

[0691] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV57-05 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0692] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV57-05 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0693] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 233), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 237), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 233 and 237), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0694] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 234, 235 and 236, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 238, 239 and 240, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0695] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 234, 235 and 236, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 238, 239 and 240, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 233 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 233), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 237 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 237), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0696] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 233), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 237), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 233 and 237, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0697] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0698] ee. Monoclonal antibody COV57-13

[0699] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV57-13 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0700] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV57-13 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0701] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 241), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 245), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising an amino acid sequence having at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identity to the amino acid sequence shown in SEQ ID NO: 241 and 245), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0702] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 242, 243 and 244, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 246, 247 and 248, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0703] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 242, 243 and 244, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 246, 247 and 248, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 241 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 241), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 245 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 245), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0704] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 241), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 245), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 241 and 245, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0705] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0706] ff. Monoclonal antibody COV57-19

[0707] In some embodiments, the antibody or antigen-binding fragment is based on or derived from a COV57-19 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0708] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV57-19 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0709] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 249), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 253), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 249 and 253), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0710] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 250, 251 and 252, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 254, 255 and 256, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0711] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 250, 251 and 252, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 254, 255 and 256, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 249 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 249), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 253 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 253), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0712] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 249), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 253), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 249 and 253, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0713] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0714] gg. Monoclonal antibody COV57-34

[0715] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV57-34 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0716] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV57-34 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0717] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 257), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 261), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 257 and 261), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0718] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 258, 259 and 260, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 262, 263 and 264, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0719] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 258, 259 and 260, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 262, 263 and 264, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 257 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 257), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 261 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 261), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0720] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 257), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 261), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 257 and 261, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0721] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0722] hh. Monoclonal antibody COV57-38

[0723] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV57-38 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0724] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV57-38 antibodies, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0725] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 265), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 269), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 265 and 269), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0726] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 266, 267 and 268, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 270, 271, and 272, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0727] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 266, 267 and 268, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 270, 271 and 272, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 265 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 265), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 269 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 269), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0728] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 265), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 269), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 265 and 269, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0729] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0730] ii. Monoclonal antibody COV57-45

[0731] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV57-45 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0732] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV57-45 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0733] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 273), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 277), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 273 and 277), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0734] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 274, 275 and 276, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 278, 279 and 280, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0735] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 274, 275 and 276, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 278, 279 and 280, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 273 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 273), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 277 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 277), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0736] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 273), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 277), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 273 and 277, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0737] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0738] jj. Monoclonal antibody COV77-02

[0739] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV77-02 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0740] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV77-02 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0741] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 281), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 285), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (respectively and independently comprising an amino acid sequence having at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identity to the amino acid sequence set forth in SEQ ID NO: 281 and 285), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0742] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 282, 283 and 284, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 286, 287 and 288, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0743] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 282, 283 and 284, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 286, 287 and 288, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 281 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 281), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 285 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 285), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0744] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 281), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 285), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 281 and 285, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0745] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0746] kk.Monoclonal antibody COV77-04

[0747] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV77-04 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0748] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV77-04 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1, OC43, NL63 and 229E.

[0749] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 289), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 293), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 289 and 293), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0750] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 290, 291 and 292, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 294, 295 and 296, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0751] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 290, 291 and 292, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 294, 295 and 296, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 289 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 289), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 293 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 293), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0752] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 289), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 293), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 289 and 293, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0753] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0754] 11. Monoclonal antibody COV77-05

[0755] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV77-05 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0756] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV77-05 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0757] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 297), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 301), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 297 and 301), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0758] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 298, 299 and 300, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 302, 303, and 304, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0759] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 298, 299 and 300, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 302, 303 and 304, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 297 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 297), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 301 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 301), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0760] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 297), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 301), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 297 and 301, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0761] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0762] mm. Monoclonal antibody COV77-09

[0763] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV77-09 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0764] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV77-09 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43. In some embodiments, the antibody or antigen-binding fragment specifically binds to the stem-helix in the S2 domain of the spike protein.

[0765] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 305), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 309), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 305 and 309), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0766] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 306, 307 and 308, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 310, 311, and 312, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0767] In some embodiments, the antibody or antigen-binding fragment comprises VH (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 306, 307 and 308, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 310, 311 and 312, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 305 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 305), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 309 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 309), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0768] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 305), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 309), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 305 and 309, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0769] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0770] nn. Monoclonal antibody COV77-14

[0771] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV77-14 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0772] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV77-14 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0773] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 313), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 317), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 313 and 317) and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0774] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 314, 315 and 316, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 318, 319, and 320, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0775] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 314, 315 and 316, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 318, 319 and 320, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 313 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 313), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 317 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 317), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0776] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 313), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 317), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 313 and 317, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0777] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0778] oo. Monoclonal antibody COV77-35

[0779] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV77-35 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0780] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV77-35 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0781] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 321), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 325), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 321 and 325), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0782] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 322, 323 and 324, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 326, 327, and 328, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0783] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 322, 323 and 324, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 326, 327 and 328, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 321 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 321), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 325 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 325), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0784] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 321), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 325), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 321 and 325, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0785] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0786] pp. Monoclonal antibody COV77-39

[0787] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV77-39 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0788] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV77-39 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1, OC43, NL63 and 229E.

[0789] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 329), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 333), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 329 and 333), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0790] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 330, 331 and 332, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 334, 335, and 336, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0791] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 330, 331 and 332, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 334, 335 and 336, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 329 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 329), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 333 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 333), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0792] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 329), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 333), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 329 and 333, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0793] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0794] qq. Monoclonal antibody COV77-42

[0795] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV77-42 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0796] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV77-42 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0797] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 337), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 341), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 337 and 341), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0798] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 338, 339 and 340, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 342, 343, and 344, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0799] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 338, 339 and 340, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 342, 343 and 344, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 337 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 337), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 341 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 341), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0800] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 337), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 341), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 337 and 341, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0801] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0802] rr. Monoclonal antibody COV77-43

[0803] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV77-43 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0804] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV77-43 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0805] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 345), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 349), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 345 and 349), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0806] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 346, 347 and 348, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 350, 351 and 352, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0807] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 346, 347 and 348, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 350, 351 and 352, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 345 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 345), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 349 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 349), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0808] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 345), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 349), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 345 and 349, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0809] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0810] ss. monoclonal antibody COV77-46

[0811] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV77-46 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0812] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV77-46 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0813] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 353), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 357), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 353 and 357), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0814] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 354, 355 and 356, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 358, 359 and 360, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0815] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 354, 355 and 356, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 358, 359 and 360, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 353 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 353), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 357 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 357), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0816] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 353), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 357), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 353 and 357, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0817] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0818] tt. Monoclonal antibody COV77-76

[0819] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV77-76 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0820] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV77-76 antibodies, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0821] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 361), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 365), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 361 and 365), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0822] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 362, 363 and 364, respectively) and / or V L (including LCDR1, LCDR2, and LCDR3 shown in SEQ ID NOs: 366, 367, and 368, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0823] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 362, 363 and 364, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 366, 367 and 368, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 361 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 361), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 365 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 365), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0824] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 361), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 365), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 361 and 365, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0825] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0826] uu.Monoclonal antibody COV93-04

[0827] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV93-04 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0828] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV93-04 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0829] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 369), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 373), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 369 and 373), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0830] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 370, 371 and 372, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 374, 375 and 376, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0831] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 370, 371 and 372, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 374, 375 and 376, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 369 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 369), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 373 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 373), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0832] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 369), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 373), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 369 and 373, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0833] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0834] vv. Monoclonal antibody COV93-08

[0835] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV93-08 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0836] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV93-08 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0837] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 377), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 381), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 377 and 381), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0838] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 378, 379 and 380, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 382, ​​383 and 384, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0839] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 378, 379 and 380, respectively), V L (comprising LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 382, ​​383 and 384, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 377 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 377), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 381 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 381), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0840] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 377), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 381), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 377 and 381, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0841] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0842] ww.Monoclonal antibody COV93-17

[0843] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV93-17 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0844] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of the COV93-17 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to a coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to spike proteins from at least three betacoronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0845] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 385), and can specifically bind to coronavirus spike and neutralize coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 389), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In another embodiment, the antibody or antigen-binding fragment includes V H and V L (independently comprising amino acid sequences that are at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequences set forth in SEQ ID NOs: 385 and 389), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0846] In some embodiments, the antibody or antigen-binding fragment comprises V H (comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 386, 387 and 388, respectively) and / or V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 390, 391 and 392, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0847] In some embodiments, the antibody or antigen-binding fragment comprises V H(comprising HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 386, 387 and 388, respectively), V L (including LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 390, 391 and 392, respectively), wherein V H comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 385 (such as 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 385), and wherein V L The antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 389 (e.g., 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 389), and the antibody or antigen-binding fragment can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In this embodiment, the changes due to sequence identity (sequence identify) fall outside the CDRs. The coronavirus can be SARS-CoV-2.

[0848] In some embodiments, the antibody or antigen-binding fragment comprises V H (including the amino acid sequence shown in SEQ ID NO: 385), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In more embodiments, the antibody or antigen-binding fragment includes V L (including the amino acid sequence shown in SEQ ID NO: 389), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. In some embodiments, the antibody or antigen-binding fragment includes V H and V L (comprising the amino acid sequences shown in SEQ ID NOs: 385 and 389, respectively), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus may be SARS-CoV-2.

[0849] In some embodiments, the disclosed antibodies can inhibit viral entry and / or replication.

[0850] xx. Monoclonal antibody COV93-18

[0851] In some embodiments, the antibody or antigen-binding fragment is based on or derived from the COV93-18 antibody and can specifically bind to the coronavirus spike protein and neutralize the coronavirus.

[0852] In some examples, the antibody or antigen-binding fragment comprises V H and V L(including HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of COV93-18 antibody, respectively (e.g., according to IMGT, Kabat or Chothia)), and can specifically bind to the coronavirus spike protein and neutralize the coronavirus. The coronavirus can be SARS-CoV-2. In some embodiments, the antibody or antigen-binding fragment specifically binds to the spike protein from at least three beta coronaviruses selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1 and OC43.

[0853] In some embodiments, the antibody or antigen-binding fragment comprises V H (including an amino acid sequence having at least 90% (such as at least 95%, at least 96%, at least 97%, at least 98% or at least 99%) identity with the amino acid sequence shown in SEQ ID NO: 393), and can specifically bind to coronavirus spike and ...

Claims

1. An isolated monoclonal antibody or antigen-binding fragment thereof, comprising a heavy chain variable region (V H ) and light chain variable region (V L ), which includes V as shown in any of the following H and V L Heavy chain complementarity determining regions (HCDR) 1, HCDR2 and HCDR3 and light chain complementarity determining regions (LCDR) 1, LCDR2 and LCDR3: (a) SEQ ID NO: 17 and 21 (COV44-79), respectively; (b) SEQ ID NO: 9 and 13 (COV44-62), respectively; (c) SEQ ID NOs: 1 and 5 (COV89-22), respectively; (d) SEQ ID NOs: 25 and 29 (COV30-14), respectively; (e) SEQ ID NOs: 33 and 37 (COV72-37), respectively; (f) SEQ ID NOs: 49 and 53 (COV91-27), respectively; (g) SEQ ID NO: 41 and 45 (COV93-03), respectively; (h) SEQ ID NO: 57 and 61 (COV49-51), respectively; (i) SEQ ID NO: 65 and 69 (COV44-74), respectively; (j) SEQ ID NOs: 73 and 77 (COV44-56), respectively; (k) SEQ ID NOs: 81 and 85 (COV44-26), respectively; (l) SEQ ID NO: 89 and 93 (COV44-54), respectively; (m) SEQ ID NO: 97 and 101 (COV23-01), respectively; (n) SEQ ID NO: 105 and 109 (COV49-03), respectively; (o) SEQ ID NOs: 113 and 117, respectively (COV49-04); (p) SEQ ID NO: 121 and 125 (COV49-05), respectively; (q) SEQ ID NOs: 129 and 133 (COV49-06), respectively; (r) SEQ ID NO: 137 and 141 (COV49-07), respectively; (s) SEQ ID NO: 145 and 149 (COV49-18), respectively; (t) SEQ ID NO: 153 and 157 (COV49-23), respectively; (u) SEQ ID NO: 161 and 165 (COV49-28), respectively; (v) SEQ ID NOs: 169 and 173 (COV49-30), respectively; (w) SEQ ID NO: 177 and 181 (COV49-33), respectively; (x) SEQ ID NO: 185 and 189 (COV49-42), respectively; (y) SEQ ID NO: 193 and 197 (COV49-47), respectively; (z) SEQ ID NOs: 201 and 205 (COV49-54), respectively; (aa) SEQ ID NO: 209 and 213 (COV57-01), respectively; (bb) SEQ ID NO: 217 and 221 (COV57-03), respectively; (cc) SEQ ID NOs: 225 and 229, respectively (COV57-04); (dd) SEQ ID NO: 233 and 237 (COV57-05), respectively; (ee) SEQ ID NO: 241 and 245 (COV57-13), respectively; (ff) SEQ ID NO: 249 and 253 (COV57-19), respectively; (gg) SEQ ID NO: 257 and 261 (COV57-34), respectively; (hh) SEQ ID NO: 265 and 269 (COV57-38), respectively; (ii) SEQ ID NOs: 273 and 277 (COV57-45), respectively; (jj) SEQ ID NO: 281 and 285 (COV77-02), respectively; (kk) SEQ ID NO: 289 and 293 (COV77-04), respectively; (ll) SEQ ID NO: 297 and 301 (COV77-05), respectively; (mm) SEQ ID NO: 305 and 309 (COV77-09), respectively; (nn) SEQ ID NO: 313 and 317 (COV77-14), respectively; (oo) are SEQ ID NOs: 321 and 325 (COV77-35), respectively; (pp) SEQ ID NO: 329 and 333 (COV77-39), respectively; (qq) SEQ ID NO: 337 and 341 (COV77-42), respectively; (rr) SEQ ID NO: 345 and 349 (COV77-43), respectively; (ss) SEQ ID NO: 353 and 357 (COV77-46), respectively; (tt) SEQ ID NO: 361 and 365 (COV77-76), respectively; (uu) are SEQ ID NOs: 369 and 373 (COV93-04), respectively; (vv) SEQ ID NO: 377 and 381 (COV93-08), respectively; (ww) are SEQ ID NOs: 385 and 389 (COV93-17), respectively; (xx) SEQ ID NO: 393 and 397 (COV93-18), respectively; (yy) are SEQ ID NOs: 401 and 405 (COV93-23), respectively; (zz) are SEQ ID NOs: 409 and 413 (COV78-36), respectively; (aaa) are SEQ ID NOs: 417 and 421 (COV93-38), respectively; (bbb) are SEQ ID NOs: 425 and 429 (COV93-60), respectively; (ccc) are SEQ ID NOs: 433 and 437 (COV93-61), respectively; (ddd) are SEQ ID NOs: 441 and 445 (COV89-03), respectively; (eee) are SEQ ID NOs: 449 and 453 (COV89-28), respectively; (fff) are SEQ ID NOs: 457 and 461 (COV30-35), respectively; (ggg) are SEQ ID NOs: 465 and 469 (COV30-80), respectively; (hhh) SEQ ID NO: 473 and 477 (COV44-25), respectively; or (iii) SEQ ID NOs: 481 and 485 (COV44-37), respectively; And wherein the monoclonal antibody specifically binds to the coronavirus spike protein.

2. The antibody or antigen-binding fragment according to claim 1, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown below: (a) SEQ ID NO: 18, 19, 20, 22, 23 (AAS) and 24; (b) SEQ ID NO: 10, 11, 12, 14, 15 (EVT) and 16; (c) SEQ ID NO: 2, 3, 4, 6, 7 (DAS) and 8; (d) SEQ ID NOs: 26, 27, 28, 30, 31 (GES) and 32; (e) SEQ ID NOs: 34, 35, 36, 38, 39 (GAS) and 40; (f) SEQ ID NOs: 50, 51, 52, 54, 55 (DAS) and 56; (g) SEQ ID NOs: 42, 43, 44, 46, 47 (GAS) and 48; (h) SEQ ID NOs: 58, 59, 60, 62, 63 (GAS) and 64; (i) SEQ ID NO: 66, 67, 68, 70, 71 (AAS) and 72; (j) SEQ ID NOs: 74, 75, 76, 78, 79 (LGS) and 80; (k) SEQ ID NOs: 82, 83, 84, 86, 87 (AAS) and 88; (1) SEQ ID NO: 90, 91, 92, 94, 95 (AAS) and 96; (m) SEQ ID NOs: 98, 99, 100, 102, 103 (DAS) and 104; (n) SEQ ID NOs: 106, 107, 108, 110, 111 (KVS) and 112; (o) SEQ ID NOs: 114, 115, 116, 118, 119 (RVS) and 120; (p) SEQ ID NOs: 122, 123, 124, 126, 127 (QVS) and 128; (q) SEQ ID NOs: 130, 131, 132, 134, 135 (KVS) and 136; (r) SEQ ID NOs: 138, 139, 140, 142, 143 (KVS) and 144; (s) SEQ ID NO: 146, 147, 148, 150, 151 (KVS) and 152; (t) SEQ ID NOs: 154, 155, 156, 158, 159 (QVS) and 160; (u) SEQ ID NOs: 162, 163, 164, 166, 167 (QVS) and 168; (v) SEQ ID NOs: 170, 171, 172, 174, 175 (KVS) and 176; (w) SEQ ID NOs: 178, 179, 180, 182, 183 (QVS) and 184; (x) SEQ ID NOs: 186, 187, 188, 190, 191 (AAS) and 192; (y) SEQ ID NOs: 194, 195, 196, 198, 199 (QVS) and 200; (z) SEQ ID NO: 202, 203, 204, 206, 207 (AAS) and 208; (aa) SEQ ID NO: 210, 211, 212, 214, 215 (TAS) and 216; (bb) SEQ ID NO: 218, 219, 220, 222, 223 (WAS) and 224; (cc) SEQ ID NO: NO: 226, 227, 228, 230, 231 (WAS) and 232; (dd) SEQ ID NO: 234, 235, 236, 238, 239 (DAS) and 240; (ee) SEQ ID NO: 242, 243, 244, 246, 247 (WAS) and 248; (ff) SEQ ID NO:250, 251, 252, 254, 25 (DAS) 5 and 256; (gg) SEQ ID NO:258, 259, 260, 262, 263 (WAS) and 264; (hh) SEQ ID NO:266, 267, 268, 270, 271 (RDN) and 272; (ii) SEQ ID NO:274, 275, 276, 278, 279 (WAS) and 280; (jj) SEQ ID NO:282, 283, 284, 286, 287 (LGS) and 288; (kk) SEQ ID NO:290, 291, 292, 294, 295 (KDS) and 296; (ll) SEQ ID NO:298, 299, 300, 302, 303 (GAS) and 304; (mm) SEQ ID NO: 306, 307, 308, 310, 311 (WAS) and 312; (nn) SEQ ID NOs: 314, 315, 316, 318, 319 (GAS) and 320; (oo) SEQ ID NOs: 322, 323, 324, 326, 327 (GAS) and 328; (pp) SEQ ID NOs: 330, 331, 332, 334, 335 (KDR) and 336; (qq) SEQ ID NOs: 338, 339, 340, 342, 343 (GAS) and 344; (rr) SEQ ID NO: 346, 347, 348, 350, 351 (LGS) and 352; (ss) SEQ ID NOs: 354, 355, 356, 358, 359 (GAS) and 360; (tt) SEQ ID NO: 362, 363, 364, 366, 367 (WAS) and 368; (uu) SEQ ID NO: 370, 371, 372, 374, 375 (WAS) and 376; (vv) SEQ ID NOs: 378, 379, 380, 382, ​​383 (KAS) and 384; (ww) SEQ ID NO: 386, 387, 388, 390, 391 (RAS) and 392; (xx) SEQ ID NO: 394, 395, 396, 398, 399 (WAS) and 400; (yy) SEQ ID NO: 402, 403, 404, 406, 407 (WAS) and 408; (zz) SEQ ID NOs: 410, 411, 412, 414, 415 (EVS) and 416; (aaa) SEQ ID NO: 418, 419, 420, 422, 423 (KAS) and 424; (bbb) SEQ ID NO: 426, 427, 428, 430, 431 (WAS) and 432; (ccc) SEQ ID NOs: 434, 435, 436, 438, 439 (EVT) and 440; (ddd) SEQ ID NOs: 442, 443, 444, 446, 447 (WAS) and 448; (eee) SEQ ID NO: 450, 451, 452, 454, 455 (ATS) and 456; (fff) SEQ ID NOs: 458, 459, 460, 462, 463 (GAS) and 464; (ggg) SEQ ID NO: 466, 467, 468, 470, 471 (WAS) and 472; (hhh) SEQ ID NO: 474, 475, 476, 478, 479 (WAS) and 480; or (iii) SEQ ID NO: 482, 483, 484, 486, 487 (LGS) and 488.

3. The antibody or antigen-binding fragment according to claim 1 or 2, wherein the V H and the V L Each includes an amino acid sequence having at least 90% identity to the amino acid sequence shown below: (a) SEQ ID NOs: 17 and 21; (b) SEQ ID NOs: 9 and 13; (c) SEQ ID NO: 1 and 5; (d) SEQ ID NOs: 25 and 29; (e) SEQ ID NOs: 33 and 37; (f) SEQ ID NOs: 49 and 53; (g) SEQ ID NOs: 41 and 45; (h) SEQ ID NOs: 57 and 61; (i) SEQ ID NOs: 65 and 69; (j) SEQ ID NOs: 73 and 77; (k) SEQ ID NOs: 81 and 85; (1) SEQ ID NO: 89 and 93; (m) SEQ ID NOs: 97 and 101; (n) SEQ ID NOs: 105 and 109; (o) SEQ ID NOs: 113 and 117; (p) SEQ ID NOs: 121 and 125; (q) SEQ ID NOs: 129 and 133; (r) SEQ ID NOs: 137 and 141; (s) SEQ ID NO: 145 and 149; (t) SEQ ID NOs: 153 and 157; (u) SEQ ID NOs: 161 and 165; (v) SEQ ID NOs: 169 and 173; (w) SEQ ID NOs: 177 and 181; (x) SEQ ID NOs: 185 and 189; (y) SEQ ID NOs: 193 and 197; (z) SEQ ID NOs: 201 and 205; (aa) SEQ ID NOs: 209 and 213; (bb) SEQ ID NOs: 217 and 221; (cc) SEQ ID NOs: 225 and 229; (dd) SEQ ID NOs: 233 and 237; (ee) SEQ ID NOs: 241 and 245; (ff) SEQ ID NOs: 249 and 253; (gg) SEQ ID NOs: 257 and 261; (hh) SEQ ID NOs: 265 and 269; (ii) SEQ ID NOs: 273 and 277; (jj) SEQ ID NOs: 281 and 285; (kk) SEQ ID NOs: 289 and 293; (ll) SEQ ID NOs: 297 and 301; (mm) SEQ ID NOs: 305 and 309; (nn) SEQ ID NOs: 313 and 317; (oo) SEQ ID NOs: 314 and 317; (oo) SEQ ID NOs: 315 and 318; (hh) SEQ ID NOs: 319 and 320; (ii) SEQ ID NOs: 321 and 322; (jj) SEQ ID NOs: 323 and 324; (kk) SEQ ID NOs: 329 and 330; (ll) SEQ ID NOs: 331 and 332; (mm) SEQ ID NOs: 332 and 333 NO:321 and 325; (pp) SEQ ID NO:329 and 333; (qq) SEQ ID NO:337 and 341; (rr) SEQ ID NO:345 and 349; (ss) SEQ ID NO:353 and 357; (tt) SEQ ID NO:361 and 365; (uu) SEQ ID NOs: 369 and 373; (vv) SEQ ID NOs: 377 and 381; (ww) SEQ ID NOs: 385 and 389; (xx) SEQ ID NOs: 393 and 397; (yy) SEQ ID NOs: 401 and 405; (zz) SEQ ID NOs: 409 and 413; (aaa) SEQ ID NO: 417 and 421; (bbb) SEQ ID NOs: 425 and 429; (ccc) SEQ ID NOs: 433 and 437; (ddd) SEQ ID NOs: 441 and 445; (eee) SEQ ID NOs: 449 and 453; (fff) SEQ ID NOs: 457 and 461; (ggg) SEQ ID NOs: 465 and 469; (hhh) SEQ ID NOs: 473 and 477; or (iii) SEQ ID NOs:481 and 485.

4. The antibody or antigen-binding fragment of any one of the preceding claims, comprising human framework regions.

5. The antibody or antigen-binding fragment according to any one of the above claims, wherein the V H and the V L They respectively include the amino acid sequences shown below: (a) SEQ ID NOs: 17 and 21; (b) SEQ ID NOs: 9 and 13; (c) SEQ ID NO: 1 and 5; (d) SEQ ID NOs: 25 and 29; (e) SEQ ID NOs: 33 and 37; (f) SEQ ID NOs: 49 and 53; (g) SEQ ID NOs: 41 and 45; (h) SEQ ID NOs: 57 and 61; (i) SEQ ID NOs: 65 and 69; (j) SEQ ID NOs: 73 and 77; (k) SEQ ID NOs: 81 and 85; (1) SEQ ID NO: 89 and 93; (m) SEQ ID NOs: 97 and 101; (n) SEQ ID NOs: 105 and 109; (o) SEQ ID NOs: 113 and 117; (p) SEQ ID NOs: 121 and 125; (q) SEQ ID NOs: 129 and 133; (r) SEQ ID NOs: 137 and 141; (s) SEQ ID NO: 145 and 149; (t) SEQ ID NOs: 153 and 157; (u) SEQ ID NOs: 161 and 165; (v) SEQ ID NOs: 169 and 173; (w) SEQ ID NOs: 177 and 181; (x) SEQ ID NOs: 185 and 189; (y) SEQ ID NOs: 193 and 197; (z) SEQ ID NOs: 201 and 205; (aa) SEQ ID NOs: 209 and 213; (bb) SEQ ID NOs: 217 and 221; (cc) SEQ ID NOs: 225 and 229; (dd) SEQ ID NOs: 233 and 237; (ee) SEQ ID NOs: 241 and 245; (ff) SEQ ID NOs: 249 and 253; (gg) SEQ ID NOs: 257 and 261; (hh) SEQ ID NOs: 265 and 269; (ii) SEQ ID NOs: 273 and 277; (jj) SEQ ID NOs: 281 and 285; (kk) SEQ ID NOs: 289 and 293; (ll) SEQ ID NOs: 297 and 301; (mm) SEQ ID NOs: 305 and 309; (nn) SEQ ID NOs: 313 and 317; (oo) SEQ ID NOs: 314 and 317; (oo) SEQ ID NOs: 315 and 318; (hh) SEQ ID NOs: 319 and 320; (ii) SEQ ID NOs: 321 and 322; (jj) SEQ ID NOs: 323 and 324; (kk) SEQ ID NOs: 329 and 330; (ll) SEQ ID NOs: 331 and 332; (mm) SEQ ID NOs: 332 and 333 NO:321 and 325; (pp) SEQ ID NO:329 and 333; (qq) SEQ ID NO:337 and 341; (rr) SEQ ID NO:345 and 349; (ss) SEQ ID NO:353 and 357; (tt) SEQ ID NO:361 and 365; (uu) SEQ ID NO:369 and 373; (vv) SEQ ID NO:377 and 381; (ww) SEQ ID NO:385 and 389; (xx) SEQ ID NO:393 and 397; (yy) SEQ ID NO:401 and 405; (zz) SEQ ID NO:409 and 413; (aaa) SEQ ID NO: 417 and 421; (bbb) SEQ ID NOs: 425 and 429; (ccc) SEQ ID NOs: 433 and 437; (ddd) SEQ ID NOs: 441 and 445; (eee) SEQ ID NOs: 449 and 453; (fff) SEQ ID NOs: 457 and 461; (ggg) SEQ ID NOs: 465 and 469; (hhh) SEQ ID NOs: 473 and 477; or (iii) SEQ ID NOs:481 and 485.

6. The antibody of any one of the above claims, wherein the antibody comprises a human constant domain.

7. The antibody according to any one of the above claims, wherein the antibody is a human antibody.

8. The antibody according to any one of the above claims, wherein the antibody is IgG.

9. The antibody of any one of the above claims, comprising a recombinant constant domain comprising a modification that increases the half-life of the antibody.

10. The antibody of claim 9, wherein the modification improves binding to the neonatal Fc receptor.

11. The antibody or antigen-binding fragment of any one of claims 1 to 10, wherein the antibody specifically binds to the N-terminal domain of the coronavirus spike protein.

12. The antibody or antigen-binding fragment of any one of claims 1 to 11, wherein the antibody specifically binds to the S domain of the coronavirus spike protein.

13. The antibody or antigen-binding fragment of any one of claims 1 to 12, wherein the antibody neutralizes SARS-CoV-2.

14. The antigen-binding fragment of any one of claims 1 to 5 or 11 to 13.

15. The antigen-binding fragment of claim 14, wherein the antigen-binding fragment is a Fv, Fab, F(ab')2, scFV or scFV2 ​​fragment.

16. The antibody or antigen-binding fragment of any one of claims 1 to 15, wherein the antibody or antigen-binding fragment specifically binds to spike proteins from at least three beta coronaviruses, the beta coronaviruses being selected from the group consisting of SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1, and OC43.

17. The antibody or antigen-binding fragment of any one of claims 1 to 16, wherein the antibody or antigen-binding fragment neutralizes betacoronavirus and alphacoronavirus.

18. The antibody or antigen-binding fragment of any one of claims 1 to 17, wherein the antibody or antigen-binding fragment specifically binds to the spike protein from SARS-CoV-2, SARS-CoV, MERS-CoV, HKU1, OC43, NL63 and 229E.

19. The antibody or antigen-binding fragment of any one of claims 1 to 16, wherein the antibody or antigen-binding fragment specifically binds to the stem-helix in the S2 domain of the spike protein.

20. The antibody or antigen-binding fragment of any one of claims 1 to 19, which is coupled to a detectable marker.

21. A bispecific antibody comprising the antibody or antigen-binding fragment according to any one of claims 1 to 20.

22. An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment according to any one of claims 1 to 20 or a V or V sequence of said antibody. H or V L .

23. according to the nucleic acid molecule described in claim 22, wherein said nucleic acid molecule is encoding said V H or V L cDNA sequence.

24. The nucleic acid molecule according to claim 22 or 23, which is operably linked to a promoter.

25. A vector comprising a nucleic acid molecule according to any one of claims 22 to 24.

26. A host cell comprising a nucleic acid molecule or a vector according to any one of claims 22 to 25.

27. A pharmaceutical composition for inhibiting coronavirus infection, comprising an effective amount of the antibody, antigen binding fragment, bispecific antibody, nucleic acid molecule or vector according to any one of the above claims; and A pharmaceutically acceptable carrier.

28. A method for producing an antibody or antigen-binding fragment that specifically binds to a coronavirus spike protein, comprising: Expressing in a host cell one or more nucleic acid molecules encoding the antibody or antigen-binding fragment of any one of claims 1 to 19; as well as The antibody or antigen-binding fragment is purified.

29. A method for detecting the presence of a coronavirus in a biological sample from a subject, comprising: contacting the biological sample with an effective amount of the antibody or antigen-binding fragment according to any one of claims 1 to 20 under conditions sufficient to form an immune complex; as well as Detecting the presence of the immune complex in the biological sample, wherein the presence of the immune complex in the biological sample indicates the presence of a coronavirus in the sample.

30. The method of claim 29, wherein detecting the presence of the immune complex in the biological sample indicates that the subject has a SARS-CoV-2, SARS-CoV, MERS-CoV, OC43, NL63, 229E or HKU1 infection.

31. The method of claim 29, wherein detecting the presence of the immune complex in the biological sample indicates that the subject has a SARS-CoV-2 infection.

32. A method for inhibiting coronavirus infection in a subject, comprising: Administering an effective amount of the antibody, antigen-binding fragment, nucleic acid molecule, vector or pharmaceutical composition according to any one of claims 1 to 27 to the subject, wherein the subject has a coronavirus infection or is at risk of a coronavirus infection.

33. The method of claim 32, wherein the coronavirus is SARS-CoV-2, SARS-CoV, MERS-CoV, OC43, NL63, 229E, or HKU1.

34. The method of claim 32, wherein the coronavirus is SARS-CoV-2.

35. Use of the antibody, antigen binding fragment, nucleic acid molecule, vector or pharmaceutical composition according to any one of claims 1 to 27 in inhibiting coronavirus infection in a subject or detecting the presence of coronavirus in a biological sample.

36. The use according to claim 33, wherein the coronavirus is SARS-CoV-2, SARS-CoV, MERS-CoV, OC43, NL63, 229E or HKU1.

37. Use according to claim 33, wherein the coronavirus is SARS-CoV-2.

Citation Information

Patent Citations

  • Process for purifying antibody

    US20020164328A1

  • Antibody composition-producing cell

    US20030115614A1

  • Glycoprotein compositions

    US20030157108A1

  • Antibody composition which specifically binds to CD20

    US20040093621A1

  • Antibody composition-containing medicament

    US20040109865A1